# background genes,# genes,category,chart color,description,FDR value,genes,network.SUID,nodes.SUID,p-value,PMID,term name,transferred FDR value,year
515,9,KEGG Pathways,,Pathways in cancer,8.20E-10,RARA|SMAD2|CDK2|GSK3B|SMAD3|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29745|29715|29733|29724|29736|29742,4.03E-12,,hsa05200,1,0
146,7,KEGG Pathways,,Gastric cancer,8.20E-10,SMAD2|CDK2|GSK3B|SMAD3|RXRB|MYC|CTNNB1,29626,29730|29727|29745|29715|29724|29736|29742,2.44E-12,,hsa05226,1,0
82,6,KEGG Pathways,,Colorectal cancer,1.25E-09,SMAD2|GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29730|29745|29715|29733|29736|29742,1.11E-11,,hsa05210,0.979848953,0
256,8,GO Cellular Component,,RNA polymerase II transcription regulator complex,2.32E-09,RARA|SMAD2|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29715|29748|29733|29724|29736|29742,1.13E-12,,GO:0090575,0.95029002,0
72,6,WikiPathways,,Chromosomal and microsatellite instability in colorectal cancer ,4.14E-09,SMAD2|GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29730|29745|29715|29733|29736|29742,5.30E-12,,WP4216,0.92260928,0
517,9,GO Cellular Component,,Transcription regulator complex,4.27E-09,RARA|SMAD2|CDK2|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29715|29748|29733|29724|29736|29742,4.17E-12,,GO:0005667,0.921131483,0
1215,11,Reactome Pathways,,Generic Transcription Pathway,8.19E-09,RARA|SMAD2|CDK2|GSK3B|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29715|29748|29733|29724|29751|29736|29742,3.59E-12,,HSA-212436,0.890001148,0
2540,12,Reactome Pathways,,Signal Transduction,1.42E-07,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29751|29736|29742,2.48E-10,,HSA-162582,0.753639816,0
99,5,KEGG Pathways,,Th17 cell differentiation,3.88E-07,RARA|SMAD2|SMAD3|JUN|RXRB,29626,29739|29730|29715|29733|29724,4.62E-09,,hsa04659,0.705595084,0
120,5,KEGG Pathways,,Cell cycle,7.86E-07,SMAD2|CDK2|GSK3B|SMAD3|MYC,29626,29730|29727|29745|29715|29736,1.17E-08,,hsa04110,0.671852563,0
2265,12,GO Biological Process,,Negative regulation of cellular metabolic process,1.00E-06,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29715|29748|29733|29751|29736|29742,6.39E-11,,GO:0031324,0.660343064,0
1592,11,GO Biological Process,,Negative regulation of cellular biosynthetic process,1.00E-06,CYP27B1|RARA|SMAD2|CDK2|GSK3B|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29715|29748|29733|29751|29736|29742,6.66E-11,,GO:0031327,0.660343064,0
26,4,WikiPathways,,Wnt/beta-catenin signaling pathway in leukemia,1.21E-06,RARA|GSK3B|MYC|CTNNB1,29626,29739|29745|29736|29742,3.09E-09,,WP3658,0.65123194,0
100,5,WikiPathways,,Wnt signaling pathway and pluripotency,1.26E-06,GSK3B|PRKCD|JUN|MYC|CTNNB1,29626,29745|29721|29733|29736|29742,4.85E-09,,WP399,0.649296565,0
322,7,TISSUES,,Cervical carcinoma cell,1.29E-06,SMAD2|CDK2|GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29730|29727|29745|29715|29733|29736|29742,5.33E-10,,BTO:0000180,0.648171873,0
141,5,KEGG Pathways,,Signaling pathways regulating pluripotency of stem cells,1.43E-06,SMAD2|GSK3B|SMAD3|MYC|CTNNB1,29626,29730|29745|29715|29736|29742,2.55E-08,,hsa04550,0.643247218,0
120,5,WikiPathways,,Cell cycle,1.43E-06,SMAD2|CDK2|GSK3B|SMAD3|MYC,29626,29730|29727|29745|29715|29736,1.17E-08,,WP179,0.643247218,0
109,5,WikiPathways,,Androgen receptor network in prostate cancer,1.43E-06,SMAD2|CDK2|SMAD3|JUN|MYC,29626,29730|29727|29715|29733|29736,7.35E-09,,WP2263,0.643247218,0
113,5,WikiPathways,,Gastrin signaling pathway,1.43E-06,GSK3B|PRKCD|JUN|MYC|CTNNB1,29626,29745|29721|29733|29736|29742,8.74E-09,,WP4659,0.643247218,0
114,5,WikiPathways,,CKAP4 signaling pathway map,1.43E-06,GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29745|29715|29733|29736|29742,9.12E-09,,WP5322,0.643247218,0
109,5,WikiPathways,,DNA damage response (only ATM dependent),1.43E-06,GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29745|29715|29733|29736|29742,7.35E-09,,WP710,0.643247218,0
1108,9,Reactome Pathways,,Developmental Biology,1.55E-06,RARA|SMAD2|CDK2|GSK3B|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29739|29730|29727|29745|29715|29748|29733|29736|29742,3.39E-09,,HSA-1266738,0.639395694,0
132,5,WikiPathways,,TGF-beta signaling pathway,1.61E-06,SMAD2|SMAD3|JUN|WWP1|MYC,29626,29730|29715|29733|29751|29736,1.85E-08,,WP366,0.637580392,0
44,4,WikiPathways,,Integrated cancer pathway,1.70E-06,SMAD2|CDK2|SMAD3|MYC,29626,29730|29727|29715|29736,2.18E-08,,WP1971,0.634980506,0
154,5,KEGG Pathways,,Wnt signaling pathway,1.88E-06,GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29745|29715|29733|29736|29742,3.92E-08,,hsa04310,0.630170025,0
154,5,KEGG Pathways,,Hippo signaling pathway,1.88E-06,SMAD2|GSK3B|SMAD3|MYC|CTNNB1,29626,29730|29745|29715|29736|29742,3.92E-08,,hsa04390,0.630170025,0
161,5,KEGG Pathways,,Hepatocellular carcinoma,1.88E-06,SMAD2|GSK3B|SMAD3|MYC|CTNNB1,29626,29730|29745|29715|29736|29742,4.86E-08,,hsa05225,0.630170025,0
62,5,GO Biological Process,,Regulation of miRNA transcription,1.93E-06,RARA|SMAD3|MYB|JUN|MYC,29626,29739|29715|29748|29733|29736,4.91E-10,,GO:1902893,0.628915433,0
49,4,WikiPathways,,TROP2 regulatory signaling,2.32E-06,CDK2|PRKCD|JUN|CTNNB1,29626,29727|29721|29733|29742,3.27E-08,,WP5300,0.620118488,0
55,4,WikiPathways,,Overlap between signal transduction pathways contributing to LMNA laminopathies,3.08E-06,SMAD2|GSK3B|SMAD3|CTNNB1,29626,29730|29745|29715|29742,5.07E-08,,WP4879,0.606574551,0
54,4,WikiPathways,,TGF-beta receptor signaling,3.08E-06,SMAD2|SMAD3|JUN|CTNNB1,29626,29730|29715|29733|29742,4.73E-08,,WP560,0.606574551,0
58,4,WikiPathways,,TGF-beta receptor signaling in skeletal dysplasias,3.46E-06,SMAD2|SMAD3|JUN|CTNNB1,29626,29730|29715|29733|29742,6.21E-08,,WP4816,0.60101387,0
87,5,GO Biological Process,,Ureteric bud development,3.94E-06,RARA|SMAD2|SMAD3|MYC|CTNNB1,29626,29739|29730|29715|29736|29742,2.48E-09,,GO:0001657,0.594804431,0
1532,10,GO Biological Process,,Negative regulation of macromolecule biosynthetic process,3.94E-06,RARA|SMAD2|CDK2|GSK3B|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29715|29748|29733|29751|29736|29742,1.92E-09,,GO:0010558,0.594804431,0
4143,13,GO Biological Process,,Regulation of cellular biosynthetic process,3.94E-06,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29715|29748|29733|29724|29751|29736|29742,1.60E-09,,GO:0031326,0.594804431,0
375,7,GO Biological Process,,Regulation of binding,3.94E-06,RARA|SMAD2|GSK3B|PRKCD|SMAD3|JUN|CTNNB1,29626,29739|29730|29745|29721|29715|29733|29742,1.51E-09,,GO:0051098,0.594804431,0
66,4,WikiPathways,,AGE/RAGE pathway,5.00E-06,SMAD2|PRKCD|SMAD3|JUN,29626,29730|29721|29715|29733,1.02E-07,,WP2324,0.583416398,0
65,4,WikiPathways,,Physico-chemical features and toxicity-associated pathways,5.00E-06,GSK3B|JUN|MYC|CTNNB1,29626,29745|29733|29736|29742,9.60E-08,,WP3680,0.583416398,0
2403,11,GO Biological Process,,Negative regulation of nitrogen compound metabolic process,5.86E-06,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29751|29736|29742,5.60E-09,,GO:0051172,0.57583042,0
210,5,KEGG Pathways,,Human T-cell leukemia virus 1 infection,5.93E-06,SMAD2|CDK2|SMAD3|JUN|MYC,29626,29730|29727|29715|29733|29736,1.77E-07,,hsa05166,0.575262846,0
74,4,WikiPathways,,"Non-genomic actions of 1,25 dihydroxyvitamin D3",7.25E-06,CYP27B1|PRKCD|JUN|RXRB,29626,29718|29721|29733|29724,1.58E-07,,WP4341,0.565656691,0
1146,9,COMPARTMENTS,,Nucleoplasm,1.05E-05,RARA|SMAD2|CDK2|GSK3B|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29739|29730|29727|29745|29715|29748|29733|29736|29742,4.56E-09,,GOCC:0005654,0.547953852,0
85,4,WikiPathways,,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,1.17E-05,GSK3B|JUN|MYC|CTNNB1,29626,29745|29733|29736|29742,2.69E-07,,WP4336,0.542781543,0
96,4,KEGG Pathways,,AGE-RAGE signaling pathway in diabetic complications,1.31E-05,SMAD2|PRKCD|SMAD3|JUN,29626,29730|29721|29715|29733,4.30E-07,,hsa04933,0.537379339,0
90,4,WikiPathways,,Androgen receptor signaling pathway,1.38E-05,GSK3B|SMAD3|JUN|CTNNB1,29626,29745|29715|29733|29742,3.35E-07,,WP138,0.534891189,0
93,4,WikiPathways,,lncRNA in canonical Wnt signaling and colorectal cancer,1.49E-05,GSK3B|JUN|MYC|CTNNB1,29626,29745|29733|29736|29742,3.81E-07,,WP4258,0.531225495,0
1322,9,GO Biological Process,,"Negative regulation of transcription, DNA-templated",1.55E-05,RARA|SMAD2|CDK2|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29715|29748|29733|29751|29736|29742,1.59E-08,,GO:0045892,0.529338517,0
1332,9,GO Biological Process,,Positive regulation of developmental process,1.55E-05,CYP27B1|RARA|SMAD2|GSK3B|SMAD3|MYB|RXRB|MYC|CTNNB1,29626,29718|29739|29730|29745|29715|29748|29724|29736|29742,1.69E-08,,GO:0051094,0.529338517,0
1363,9,GO Biological Process,,Response to endogenous stimulus,1.62E-05,CYP27B1|RARA|SMAD2|GSK3B|PRKCD|SMAD3|JUN|RXRB|CTNNB1,29626,29718|29739|29730|29745|29721|29715|29733|29724|29742,2.07E-08,,GO:0009719,0.527227255,0
97,4,WikiPathways,,B cell receptor signaling pathway,1.67E-05,GSK3B|PRKCD|JUN|MYC,29626,29745|29721|29733|29736,4.48E-07,,WP23,0.52577434,0
98,4,WikiPathways,,Hippo signaling regulation pathways,1.67E-05,SMAD2|PRKCD|SMAD3|CTNNB1,29626,29730|29721|29715|29742,4.66E-07,,WP4540,0.52577434,0
2760,11,GO Biological Process,,Negative regulation of macromolecule metabolic process,1.69E-05,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29751|29736|29742,2.47E-08,,GO:0010605,0.525205319,0
2749,11,GO Biological Process,,Regulation of multicellular organismal process,1.69E-05,CYP27B1|RARA|SMAD2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29718|29739|29730|29745|29721|29715|29748|29733|29724|29736|29742,2.36E-08,,GO:0051239,0.525205319,0
100,4,WikiPathways,,Neural crest differentiation,1.71E-05,GSK3B|MYB|MYC|CTNNB1,29626,29745|29748|29736|29742,5.04E-07,,WP2064,0.524642992,0
2041,10,GO Biological Process,,Positive regulation of cellular biosynthetic process,1.98E-05,RARA|SMAD2|CDK2|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29721|29715|29748|29733|29724|29736|29742,3.10E-08,,GO:0031328,0.517635753,0
2056,10,GO Biological Process,,Positive regulation of nucleobase-containing compound metabolic process,1.98E-05,RARA|SMAD2|CDK2|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29721|29715|29748|29733|29724|29736|29742,3.33E-08,,GO:0045935,0.517635753,0
48,4,GO Biological Process,,Positive regulation of miRNA transcription,1.98E-05,SMAD3|MYB|JUN|MYC,29626,29715|29748|29733|29736,3.02E-08,,GO:1902895,0.517635753,0
271,5,WikiPathways,,IL-18 signaling pathway,1.98E-05,GSK3B|PRKCD|JUN|RXRB|CTNNB1,29626,29745|29721|29733|29724|29742,6.09E-07,,WP4754,0.517635753,0
59,4,Reactome Pathways,,Transcriptional regulation of granulopoiesis,2.52E-05,RARA|CDK2|MYB|MYC,29626,29739|29727|29748|29736,6.63E-08,,HSA-9616222,0.506108876,0
3980,12,GO Biological Process,,Regulation of macromolecule biosynthetic process,2.57E-05,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29751|29736|29742,4.97E-08,,GO:0010556,0.505169804,0
9,3,GO Biological Process,,Embryonic foregut morphogenesis,2.57E-05,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,4.91E-08,,GO:0048617,0.505169804,0
114,4,WikiPathways,,Wnt signaling,2.61E-05,GSK3B|JUN|MYC|CTNNB1,29626,29745|29733|29736|29742,8.37E-07,,WP428,0.504431608,0
120,4,KEGG Pathways,,Thyroid hormone signaling pathway,2.86E-05,GSK3B|RXRB|MYC|CTNNB1,29626,29745|29724|29736|29742,1.02E-06,,hsa04919,0.500059529,0
1547,9,GO Biological Process,,Response to oxygen-containing compound,3.05E-05,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|JUN|RXRB|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29733|29724|29742,6.21E-08,,GO:1901700,0.496985213,0
30,3,WikiPathways,,Extracellular vesicle-mediated signaling in recipient cells,3.63E-05,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,1.21E-06,,WP2870,0.488664144,0
3114,11,GO Biological Process,,Positive regulation of cellular metabolic process,4.00E-05,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29736|29742,8.93E-08,,GO:0031325,0.484024863,0
1103,8,GO Biological Process,,Cellular response to endogenous stimulus,4.21E-05,RARA|SMAD2|GSK3B|PRKCD|SMAD3|JUN|RXRB|CTNNB1,29626,29739|29730|29745|29721|29715|29733|29724|29742,9.92E-08,,GO:0071495,0.481579161,0
3166,11,GO Biological Process,,Positive regulation of nitrogen compound metabolic process,4.40E-05,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29736|29742,1.07E-07,,GO:0051173,0.479469301,0
713,7,GO Biological Process,,Negative regulation of cell population proliferation,4.80E-05,CYP27B1|RARA|SMAD2|SMAD3|JUN|MYC|CTNNB1,29626,29718|29739|29730|29715|29733|29736|29742,1.19E-07,,GO:0008285,0.475310399,0
14,3,Reactome Pathways,,Formation of axial mesoderm,4.94E-05,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,1.52E-07,,HSA-9796292,0.473936257,0
150,4,KEGG Pathways,,Cellular senescence,5.64E-05,SMAD2|CDK2|SMAD3|MYC,29626,29730|29727|29715|29736,2.42E-06,,hsa04218,0.467602229,0
37,3,KEGG Pathways,,Thyroid cancer,5.64E-05,RXRB|MYC|CTNNB1,29626,29724|29736|29742,2.18E-06,,hsa05216,0.467602229,0
146,4,KEGG Pathways,,Breast cancer,5.64E-05,GSK3B|JUN|MYC|CTNNB1,29626,29745|29733|29736|29742,2.18E-06,,hsa05224,0.467602229,0
1710,9,GO Biological Process,,"Positive regulation of transcription, DNA-templated",5.80E-05,RARA|SMAD2|CDK2|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29715|29748|29733|29724|29736|29742,1.48E-07,,GO:0045893,0.466265157,0
5899,13,GO Biological Process,,Regulation of primary metabolic process,5.80E-05,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29715|29748|29733|29724|29751|29736|29742,1.57E-07,,GO:0080090,0.466265157,0
143,4,WikiPathways,,Brain-derived neurotrophic factor (BDNF) signaling pathway,5.83E-05,GSK3B|PRKCD|JUN|CTNNB1,29626,29745|29721|29733|29742,2.01E-06,,WP2380,0.466018567,0
36,3,WikiPathways,,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling,5.83E-05,SMAD2|GSK3B|SMAD3,29626,29730|29745|29715,2.02E-06,,WP3850,0.466018567,0
157,4,KEGG Pathways,,Hepatitis C,6.08E-05,CDK2|GSK3B|MYC|CTNNB1,29626,29727|29745|29736|29742,2.89E-06,,hsa05160,0.464011671,0
158,4,KEGG Pathways,,Hepatitis B,6.08E-05,CDK2|SMAD3|JUN|MYC,29626,29727|29715|29733|29736,2.97E-06,,hsa05161,0.464011671,0
150,4,WikiPathways,,Hepatitis B infection,6.53E-05,SMAD2|SMAD3|JUN|MYC,29626,29730|29715|29733|29736,2.42E-06,,WP4666,0.460598842,0
40,3,WikiPathways,,IL-5 signaling pathway,6.99E-05,GSK3B|JUN|MYC,29626,29745|29733|29736,2.72E-06,,WP127,0.457345112,0
154,4,WikiPathways,,Breast cancer pathway,6.99E-05,GSK3B|JUN|MYC|CTNNB1,29626,29745|29733|29736|29742,2.69E-06,,WP4262,0.457345112,0
17,3,Reactome Pathways,,Germ layer formation at gastrulation,7.24E-05,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,2.54E-07,,HSA-9754189,0.455665487,0
42,3,WikiPathways,,TNF-related weak inducer of apoptosis (TWEAK) signaling pathway,7.60E-05,GSK3B|JUN|CTNNB1,29626,29745|29733|29742,3.13E-06,,WP2036,0.453346029,0
160,4,WikiPathways,,Epithelial to mesenchymal transition in colorectal cancer,7.60E-05,SMAD2|GSK3B|SMAD3|CTNNB1,29626,29730|29745|29715|29742,3.11E-06,,WP4239,0.453346029,0
1250,8,GO Biological Process,,Positive regulation of transcription by RNA polymerase II,9.25E-05,RARA|SMAD2|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29715|29748|29733|29724|29736|29742,2.60E-07,,GO:0045944,0.443955055,0
1067,8,TISSUES,,Leukemia cell,9.31E-05,SMAD2|CDK2|GSK3B|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29730|29727|29745|29715|29748|29733|29736|29742,7.68E-08,,BTO:0001271,0.44364602,0
3533,11,GO Biological Process,,Positive regulation of macromolecule metabolic process,1.10E-04,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29736|29742,3.41E-07,,GO:0010604,0.435673147,0
2609,10,GO Biological Process,,Cellular response to chemical stimulus,1.10E-04,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29733|29724|29736|29742,3.29E-07,,GO:0070887,0.435673147,0
187,4,KEGG Pathways,,Kaposi sarcoma-associated herpesvirus infection,1.10E-04,GSK3B|JUN|MYC|CTNNB1,29626,29745|29733|29736|29742,5.70E-06,,hsa05167,0.435673147,0
48,3,WikiPathways,,Hepatitis C and hepatocellular carcinoma,1.10E-04,SMAD3|JUN|MYC,29626,29715|29733|29736,4.58E-06,,WP3646,0.435673147,0
51,3,WikiPathways,,Wnt signaling pathway,1.20E-04,GSK3B|MYC|CTNNB1,29626,29745|29736|29742,5.45E-06,,WP363,0.431514245,0
434,5,WikiPathways,,Malignant pleural mesothelioma,1.30E-04,CDK2|GSK3B|JUN|MYC|CTNNB1,29626,29727|29745|29733|29736|29742,5.95E-06,,WP5087,0.427688426,0
52,3,WikiPathways,,NRP1-triggered signaling pathways in pancreatic cancer ,1.30E-04,SMAD2|CDK2|SMAD3,29626,29730|29727|29715,5.76E-06,,WP5144,0.427688426,0
2692,10,GO Biological Process,,Response to organic substance,1.40E-04,CYP27B1|RARA|SMAD2|GSK3B|PRKCD|SMAD3|JUN|RXRB|MYC|CTNNB1,29626,29718|29739|29730|29745|29721|29715|29733|29724|29736|29742,4.44E-07,,GO:0010033,0.42414627,0
876,7,GO Biological Process,,Positive regulation of cell differentiation,1.40E-04,CYP27B1|RARA|SMAD2|GSK3B|SMAD3|MYB|CTNNB1,29626,29718|29739|29730|29745|29715|29748|29742,4.79E-07,,GO:0045597,0.42414627,0
97,4,GO Biological Process,,Negative regulation of myeloid cell differentiation,1.40E-04,RARA|MYB|MYC|CTNNB1,29626,29739|29748|29736|29742,4.48E-07,,GO:0045638,0.42414627,0
58,3,KEGG Pathways,,Endometrial cancer,1.40E-04,GSK3B|MYC|CTNNB1,29626,29745|29736|29742,7.89E-06,,hsa05213,0.42414627,0
59,3,KEGG Pathways,,Inflammatory bowel disease,1.40E-04,SMAD2|SMAD3|JUN,29626,29730|29715|29733,8.29E-06,,hsa05321,0.42414627,0
265,5,Reactome Pathways,,Signaling by Nuclear Receptors,1.40E-04,RARA|MYB|JUN|RXRB|MYC,29626,29739|29748|29733|29724|29736,5.47E-07,,HSA-9006931,0.42414627,0
587,7,GO Molecular Function,,Transcription factor binding,1.60E-04,RARA|SMAD2|GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29739|29730|29745|29715|29733|29736|29742,3.19E-08,,GO:0008134,0.41776384,0
442,6,TISSUES,,Bone marrow cancer cell,1.60E-04,SMAD2|GSK3B|SMAD3|MYB|JUN|MYC,29626,29730|29745|29715|29748|29733|29736,2.00E-07,,BTO:0000583,0.41776384,0
4899,12,GO Biological Process,,Regulation of gene expression,1.70E-04,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29751|29736|29742,5.67E-07,,GO:0010468,0.414866151,0
3759,11,GO Biological Process,,Regulation of RNA metabolic process,1.90E-04,RARA|SMAD2|CDK2|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29721|29715|29748|29733|29724|29751|29736|29742,6.57E-07,,GO:0051252,0.409549875,0
63,3,WikiPathways,,Endometrial cancer,2.10E-04,GSK3B|MYC|CTNNB1,29626,29745|29736|29742,1.00E-05,,WP4155,0.404766163,0
539,7,Monarch Phenotype,,Pain,2.20E-04,CYP27B1|RARA|SMAD2|PRKCD|SMAD3|MYC|CTNNB1,29626,29718|29739|29730|29721|29715|29736|29742,1.79E-08,,HP:0012531,0.402542636,0
66,3,WikiPathways,,Thyroid stimulating hormone (TSH) signaling pathway,2.30E-04,CDK2|JUN|MYC,29626,29727|29733|29736,1.14E-05,,WP2032,0.400417965,0
69,3,WikiPathways,,Th17 cell differentiation pathway,2.50E-04,RARA|SMAD2|JUN,29626,29739|29730|29733,1.30E-05,,WP5130,0.396432555,0
971,7,GO Biological Process,,Negative regulation of transcription by RNA polymerase II,2.60E-04,RARA|CDK2|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29739|29727|29715|29748|29733|29736|29742,9.56E-07,,GO:0000122,0.394557914,0
2131,9,GO Biological Process,,Positive regulation of response to stimulus,2.60E-04,CYP27B1|RARA|SMAD2|PRKCD|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29718|29739|29730|29721|29715|29748|29733|29736|29742,9.80E-07,,GO:0048584,0.394557914,0
1505,8,GO Biological Process,,Positive regulation of multicellular organismal process,2.80E-04,CYP27B1|RARA|SMAD2|SMAD3|MYB|RXRB|MYC|CTNNB1,29626,29718|29739|29730|29715|29748|29724|29736|29742,1.07E-06,,GO:0051240,0.391015759,0
1518,8,GO Biological Process,,Intracellular signal transduction,2.90E-04,SMAD2|CDK2|GSK3B|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29730|29727|29745|29721|29715|29733|29736|29742,1.15E-06,,GO:0035556,0.389338491,0
4010,11,GO Biological Process,,Response to chemical,3.20E-04,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|JUN|RXRB|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29715|29733|29724|29736|29742,1.30E-06,,GO:0042221,0.384633329,0
81,3,KEGG Pathways,,ErbB signaling pathway,3.30E-04,GSK3B|JUN|MYC,29626,29745|29733|29736,2.07E-05,,hsa04012,0.383162529,0
76,3,WikiPathways,,Prolactin signaling pathway,3.30E-04,GSK3B|JUN|MYC,29626,29745|29733|29736,1.72E-05,,WP2037,0.383162529,0
476,6,COMPARTMENTS,,Chromatin,3.40E-04,RARA|SMAD2|SMAD3|JUN|MYC|CTNNB1,29626,29739|29730|29715|29733|29736|29742,3.07E-07,,GOCC:0000785,0.38173564,0
1582,8,GO Biological Process,,Regulation of cell differentiation,3.70E-04,CYP27B1|RARA|SMAD2|GSK3B|SMAD3|MYB|MYC|CTNNB1,29626,29718|29739|29730|29745|29715|29748|29736|29742,1.57E-06,,GO:0045595,0.377694031,0
458,6,GO Molecular Function,,"DNA-binding transcription activator activity, RNA polymerase II-specific",3.70E-04,SMAD2|SMAD3|MYB|JUN|RXRB|MYC,29626,29730|29715|29748|29733|29724|29736,2.46E-07,,GO:0001228,0.377694031,0
78,4,GO Molecular Function,,SMAD binding,3.70E-04,SMAD2|SMAD3|JUN|CTNNB1,29626,29730|29715|29733|29742,1.93E-07,,GO:0046332,0.377694031,0
14,3,GO Molecular Function,,I-SMAD binding,3.70E-04,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,1.52E-07,,GO:0070411,0.377694031,0
484,6,GO Molecular Function,,DNA-binding transcription factor binding,3.70E-04,SMAD2|GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29730|29745|29715|29733|29736|29742,3.39E-07,,GO:0140297,0.377694031,0
9,2,WikiPathways,,Vitamin D metabolism,4.10E-04,CYP27B1|RXRB,29626,29718|29724,2.20E-05,,WP1531,0.372787448,0
91,3,KEGG Pathways,,TGF-beta signaling pathway,4.40E-04,SMAD2|SMAD3|MYC,29626,29730|29715|29736,2.90E-05,,hsa04350,0.369412124,0
92,3,KEGG Pathways,,Small cell lung cancer,4.40E-04,CDK2|RXRB|MYC,29626,29727|29724|29736,2.99E-05,,hsa05222,0.369412124,0
86,3,WikiPathways,,Pancreatic adenocarcinoma pathway,4.50E-04,SMAD2|PRKCD|SMAD3,29626,29730|29721|29715,2.46E-05,,WP4263,0.368337984,0
24,3,GO Molecular Function,,R-SMAD binding,4.60E-04,SMAD2|SMAD3|JUN,29626,29730|29715|29733,6.49E-07,,GO:0070412,0.367287453,0
36,3,Reactome Pathways,,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,4.60E-04,SMAD2|SMAD3|MYC,29626,29730|29715|29736,2.02E-06,,HSA-2173796,0.367287453,0
951,7,COMPARTMENTS,,Chromosome,4.80E-04,RARA|SMAD2|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29739|29730|29715|29748|29733|29736|29742,8.31E-07,,GOCC:0005694,0.365253222,0
2902,10,COMPARTMENTS,,Intracellular organelle lumen,4.80E-04,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29736|29742,9.08E-07,,GOCC:0070013,0.365253222,0
89,3,WikiPathways,,ErbB signaling pathway,4.80E-04,GSK3B|JUN|MYC,29626,29745|29733|29736,2.72E-05,,WP673,0.365253222,0
97,3,KEGG Pathways,,Prostate cancer,4.90E-04,CDK2|GSK3B|CTNNB1,29626,29727|29745|29742,3.49E-05,,hsa05215,0.364267677,0
669,6,GO Biological Process,,Tube morphogenesis,5.10E-04,RARA|SMAD2|SMAD3|JUN|MYC|CTNNB1,29626,29739|29730|29715|29733|29736|29742,2.20E-06,,GO:0035239,0.362355533,0
114,4,GO Molecular Function,,Transcription coregulator binding,5.20E-04,RARA|SMAD3|MYC|CTNNB1,29626,29739|29715|29736|29742,8.37E-07,,GO:0001221,0.361427402,0
92,3,WikiPathways,,Corticotropin-releasing hormone signaling pathway,5.20E-04,GSK3B|PRKCD|CTNNB1,29626,29745|29721|29742,2.99E-05,,WP2355,0.361427402,0
1669,8,GO Biological Process,,Regulation of cell population proliferation,5.30E-04,CYP27B1|RARA|SMAD2|CDK2|SMAD3|JUN|MYC|CTNNB1,29626,29718|29739|29730|29727|29715|29733|29736|29742,2.35E-06,,GO:0042127,0.360516951,0
95,3,WikiPathways,,Small cell lung cancer,5.60E-04,CDK2|RXRB|MYC,29626,29727|29724|29736,3.29E-05,,WP4658,0.357885247,0
685,6,GO Biological Process,,Negative regulation of cell differentiation,5.70E-04,RARA|GSK3B|SMAD3|MYB|MYC|CTNNB1,29626,29739|29745|29715|29748|29736|29742,2.52E-06,,GO:0045596,0.357039256,0
1702,8,Reactome Pathways,,Disease,5.70E-04,CYP27B1|SMAD2|CDK2|GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29718|29730|29727|29745|29715|29733|29736|29742,2.73E-06,,HSA-1643685,0.357039256,0
5584,12,GO Biological Process,,Positive regulation of cellular process,5.80E-04,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29715|29748|29733|29724|29736|29742,2.61E-06,,GO:0048522,0.356207979,0
1723,8,GO Biological Process,,Tissue development,6.50E-04,CYP27B1|RARA|SMAD2|GSK3B|SMAD3|JUN|MYC|CTNNB1,29626,29718|29739|29730|29745|29715|29733|29736|29742,2.99E-06,,GO:0009888,0.35076176,0
112,3,KEGG Pathways,,Neurotrophin signaling pathway,7.10E-04,GSK3B|PRKCD|JUN,29626,29745|29721|29733,5.30E-05,,hsa04722,0.346541618,0
5734,12,GO Biological Process,,Regulation of nitrogen compound metabolic process,7.60E-04,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29751|29736|29742,3.55E-06,,GO:0051171,0.343288852,0
3,2,Reactome Pathways,,SMAD4 MH2 Domain Mutants in Cancer,7.60E-04,SMAD2|SMAD3,29626,29730|29715,4.01E-06,,HSA-3311021,0.343288852,0
3,2,Reactome Pathways,,SMAD2/3 MH2 Domain Mutants in Cancer,7.60E-04,SMAD2|SMAD3,29626,29730|29715,4.01E-06,,HSA-3315487,0.343288852,0
430,5,Reactome Pathways,,Diseases of signal transduction by growth factor receptors and second messengers,7.60E-04,SMAD2|GSK3B|SMAD3|MYC|CTNNB1,29626,29730|29745|29715|29736|29742,5.69E-06,,HSA-5663202,0.343288852,0
411,6,Monarch Phenotype,,Abnormal bleeding,8.00E-04,RARA|SMAD2|PRKCD|SMAD3|MYC|CTNNB1,29626,29739|29730|29721|29715|29736|29742,1.31E-07,,HP:0001892,0.340837174,0
5278,12,UniProt Keywords,,Nucleus,9.10E-04,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29751|29736|29742,1.35E-06,,KW-0539,0.334679321,0
336,4,WikiPathways,,PI3K-Akt signaling pathway,9.10E-04,CDK2|GSK3B|MYB|MYC,29626,29727|29745|29748|29736,5.50E-05,,WP4172,0.334679321,0
116,3,WikiPathways,,Embryonic stem cell pluripotency pathways,9.60E-04,GSK3B|JUN|CTNNB1,29626,29745|29733|29742,5.87E-05,,WP3931,0.33212271,0
16,2,WikiPathways,,MAPK pathway in congenital thyroid cancer,9.70E-04,JUN|MYC,29626,29733|29736,6.11E-05,,WP4928,0.331627398,0
3460,10,GO Biological Process,,"Regulation of transcription, DNA-templated",9.90E-04,RARA|SMAD2|CDK2|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29715|29748|29733|29724|29751|29736|29742,4.80E-06,,GO:0006355,0.33065191,0
2586,9,GO Biological Process,,Regulation of transcription by RNA polymerase II,0.001,RARA|SMAD2|CDK2|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29715|29748|29733|29724|29736|29742,5.08E-06,,GO:0006357,0.330171532,0
419,5,GO Biological Process,,Gland development,0.001,RARA|SMAD2|SMAD3|JUN|CTNNB1,29626,29739|29730|29715|29733|29742,5.02E-06,,GO:0048732,0.330171532,0
4169,11,GO Cellular Component,,Nucleoplasm,0.001,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29736|29742,1.96E-06,,GO:0005654,0.330171532,0
51,3,GO Biological Process,,Positive regulation of epithelial to mesenchymal transition,0.0011,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,5.45E-06,,GO:0010718,0.32561597,0
2622,9,GO Biological Process,,Regulation of protein metabolic process,0.0011,RARA|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29739|29727|29745|29721|29715|29748|29733|29736|29742,5.71E-06,,GO:0051246,0.32561597,0
133,3,KEGG Pathways,,Estrogen signaling pathway,0.0011,RARA|PRKCD|JUN,29626,29739|29721|29733,8.73E-05,,hsa04915,0.32561597,0
17,2,WikiPathways,,Regulation of Wnt / B-catenin signaling by small molecule compounds,0.0011,GSK3B|CTNNB1,29626,29745|29742,6.82E-05,,WP3664,0.32561597,0
17,2,WikiPathways,,TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition,0.0011,SMAD2|SMAD3,29626,29730|29715,6.82E-05,,WP3859,0.32561597,0
17,2,WikiPathways,,Canonical and non-canonical TGF-B signaling,0.0011,SMAD2|SMAD3,29626,29730|29715,6.82E-05,,WP3874,0.32561597,0
17,2,WikiPathways,,MAP3K1 role in promoting and blocking gonadal determination,0.0011,GSK3B|CTNNB1,29626,29745|29742,6.82E-05,,WP4872,0.32561597,0
53,3,GO Biological Process,,Negative regulation of myeloid leukocyte differentiation,0.0012,RARA|MYC|CTNNB1,29626,29739|29736|29742,6.09E-06,,GO:0002762,0.321457068,0
353,5,GO Molecular Function,,RNA polymerase II-specific DNA-binding transcription factor binding,0.0012,SMAD2|GSK3B|SMAD3|JUN|CTNNB1,29626,29730|29745|29715|29733|29742,2.19E-06,,GO:0061629,0.321457068,0
137,3,KEGG Pathways,,Measles,0.0012,CDK2|GSK3B|JUN,29626,29727|29745|29733,9.52E-05,,hsa05162,0.321457068,0
130,3,WikiPathways,,Adipogenesis,0.0012,RARA|SMAD3|CTNNB1,29626,29739|29715|29742,8.17E-05,,WP236,0.321457068,0
4714,11,GO Biological Process,,Signal transduction,0.0013,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29733|29724|29751|29736|29742,7.08E-06,,GO:0007165,0.317631248,0
827,6,GO Biological Process,,Response to lipid,0.0014,CYP27B1|RARA|SMAD2|GSK3B|RXRB|CTNNB1,29626,29718|29739|29730|29745|29724|29742,7.44E-06,,GO:0033993,0.314089093,0
6,2,Reactome Pathways,,SMAD2/3 Phosphorylation Motif Mutants in Cancer,0.0014,SMAD2|SMAD3,29626,29730|29715,1.12E-05,,HSA-3304356,0.314089093,0
6,2,Reactome Pathways,,TGFBR1 KD Mutants in Cancer,0.0014,SMAD2|SMAD3,29626,29730|29715,1.12E-05,,HSA-3656532,0.314089093,0
140,3,WikiPathways,,Endoderm differentiation,0.0014,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,1.00E-04,,WP2853,0.314089093,0
21,2,WikiPathways,,PI3K/AKT/mTOR - vitamin D3 signaling,0.0014,GSK3B|MYC,29626,29745|29736,1.00E-04,,WP4141,0.314089093,0
22,2,WikiPathways,,Regulation of apoptosis by parathyroid hormone-related protein,0.0015,GSK3B|MYC,29626,29745|29736,1.10E-04,,WP3872,0.310791425,0
22,2,WikiPathways,,Progeria-associated lipodystrophy,0.0015,SMAD2|SMAD3,29626,29730|29715,1.10E-04,,WP5103,0.310791425,0
244,5,Monarch Phenotype,,Internal hemorrhage,0.0015,RARA|SMAD2|SMAD3|MYC|CTNNB1,29626,29739|29730|29715|29736|29742,3.66E-07,,HP:0011029,0.310791425,0
153,3,KEGG Pathways,,Cushing syndrome,0.0016,CDK2|GSK3B|CTNNB1,29626,29727|29745|29742,1.30E-04,,hsa04934,0.307706663,0
4,2,COMPARTMENTS,,Homomeric SMAD protein complex,0.0017,SMAD2|SMAD3,29626,29730|29715,6.01E-06,,GOCC:0071142,0.304808974,0
861,6,GO Biological Process,,Response to organic cyclic compound,0.0017,CYP27B1|RARA|SMAD2|GSK3B|RXRB|CTNNB1,29626,29718|29739|29730|29745|29724|29742,9.36E-06,,GO:0014070,0.304808974,0
2019,8,GO Biological Process,,Cellular response to organic substance,0.0017,RARA|SMAD2|GSK3B|PRKCD|SMAD3|JUN|RXRB|CTNNB1,29626,29739|29730|29745|29721|29715|29733|29724|29742,9.87E-06,,GO:0071310,0.304808974,0
64,3,GO Biological Process,,Positive regulation of nucleocytoplasmic transport,0.0018,GSK3B|PRKCD|SMAD3,29626,29745|29721|29715,1.05E-05,,GO:0046824,0.302076961,0
64,3,GO Biological Process,,SMAD protein signal transduction,0.0018,SMAD2|SMAD3|JUN,29626,29730|29715|29733,1.05E-05,,GO:0060395,0.302076961,0
1389,7,GO Biological Process,,Regulation of multicellular organismal development,0.0018,CYP27B1|RARA|SMAD3|MYB|RXRB|MYC|CTNNB1,29626,29718|29739|29715|29748|29724|29736|29742,1.03E-05,,GO:2000026,0.302076961,0
25,2,WikiPathways,,IL-7 signaling pathway,0.0018,GSK3B|MYC,29626,29745|29736,1.40E-04,,WP205,0.302076961,0
25,2,WikiPathways,,Hypothesized pathways in pathogenesis of cardiovascular disease,0.0018,SMAD2|SMAD3,29626,29730|29715,1.40E-04,,WP3668,0.302076961,0
428,4,WikiPathways,,VEGFA-VEGFR2 signaling,0.0018,GSK3B|PRKCD|JUN|CTNNB1,29626,29745|29721|29733|29742,1.40E-04,,WP3888,0.302076961,0
159,3,WikiPathways,,Insulin signaling,0.0018,GSK3B|PRKCD|JUN,29626,29745|29721|29733,1.50E-04,,WP481,0.302076961,0
154,3,WikiPathways,,Sudden infant death syndrome (SIDS) susceptibility pathways,0.0018,MYB|JUN|CTNNB1,29626,29748|29733|29742,1.30E-04,,WP706,0.302076961,0
891,6,GO Biological Process,,Negative regulation of apoptotic process,0.0019,GSK3B|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29745|29721|29715|29733|29736|29742,1.14E-05,,GO:0043066,0.299492697,0
1285,7,GO Cellular Component,,Chromatin,0.0019,RARA|SMAD2|SMAD3|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29715|29733|29724|29736|29742,6.18E-06,,GO:0000785,0.299492697,0
1850,8,GO Cellular Component,,Chromosome,0.0019,RARA|SMAD2|CDK2|SMAD3|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29715|29733|29724|29736|29742,5.12E-06,,GO:0005694,0.299492697,0
1196,7,GO Molecular Function,,RNA polymerase II cis-regulatory region sequence-specific DNA binding,0.0019,RARA|SMAD2|SMAD3|MYB|JUN|RXRB|MYC,29626,29739|29730|29715|29748|29733|29724|29736,3.84E-06,,GO:0000978,0.299492697,0
8,2,Reactome Pathways,,Binding of TCF/LEF:CTNNB1 to target gene promoters,0.0019,MYC|CTNNB1,29626,29736|29742,1.80E-05,,HSA-4411364,0.299492697,0
8,2,Reactome Pathways,,RUNX3 regulates WNT signaling,0.0019,MYC|CTNNB1,29626,29736|29742,1.80E-05,,HSA-8951430,0.299492697,0
229,4,GO Biological Process,,Skeletal system morphogenesis,0.002,RARA|SMAD2|SMAD3|CTNNB1,29626,29739|29730|29715|29742,1.25E-05,,GO:0048705,0.29704102,0
503,5,GO Biological Process,,Response to growth factor,0.002,SMAD2|SMAD3|JUN|MYC|CTNNB1,29626,29730|29715|29733|29736|29742,1.21E-05,,GO:0070848,0.29704102,0
4787,11,COMPARTMENTS,,Nucleus,0.0021,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29736|29742,8.30E-06,,GOCC:0005634,0.294708986,0
171,3,KEGG Pathways,,Transcriptional misregulation in cancer,0.0021,RARA|RXRB|MYC,29626,29739|29724|29736,1.80E-04,,hsa05202,0.294708986,0
3867,10,GO Biological Process,,System development,0.0022,CYP27B1|RARA|SMAD2|GSK3B|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29745|29715|29748|29733|29751|29736|29742,1.36E-05,,GO:0048731,0.292485458,0
7,2,GO Biological Process,,SMAD protein complex assembly,0.0023,SMAD2|SMAD3,29626,29730|29715,1.44E-05,,GO:0007183,0.290360787,0
1462,7,GO Biological Process,,Regulation of apoptotic process,0.0023,RARA|GSK3B|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29739|29745|29721|29715|29733|29736|29742,1.45E-05,,GO:0042981,0.290360787,0
3931,10,GO Biological Process,,Regulation of response to stimulus,0.0023,CYP27B1|RARA|SMAD2|GSK3B|PRKCD|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29718|29739|29730|29745|29721|29715|29748|29733|29736|29742,1.59E-05,,GO:0048583,0.290360787,0
238,4,GO Biological Process,,Mesenchyme development,0.0023,SMAD2|GSK3B|SMAD3|CTNNB1,29626,29730|29745|29715|29742,1.45E-05,,GO:0060485,0.290360787,0
72,3,GO Biological Process,,Regulation of cartilage development,0.0023,RARA|SMAD3|CTNNB1,29626,29739|29715|29742,1.47E-05,,GO:0061035,0.290360787,0
74,3,GO Biological Process,,Cranial skeletal system development,0.0023,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,1.59E-05,,GO:1904888,0.290360787,0
5117,11,GO Biological Process,,Anatomical structure development,0.0024,CYP27B1|RARA|SMAD2|GSK3B|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29745|29715|29748|29733|29724|29751|29736|29742,1.66E-05,,GO:0048856,0.288326556,0
76,3,GO Biological Process,,Embryonic pattern specification,0.0025,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,1.72E-05,,GO:0009880,0.286375378,0
548,5,GO Biological Process,,Heart development,0.0026,RARA|SMAD2|SMAD3|JUN|CTNNB1,29626,29739|29730|29715|29733|29742,1.82E-05,,GO:0007507,0.284500737,0
1525,7,GO Biological Process,,Positive regulation of signal transduction,0.0026,CYP27B1|SMAD2|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29718|29730|29721|29715|29733|29736|29742,1.91E-05,,GO:0009967,0.284500737,0
31,2,WikiPathways,,Gastric cancer network 2,0.0026,MYC|CTNNB1,29626,29736|29742,2.10E-04,,WP2363,0.284500737,0
32,2,WikiPathways,,Hair follicle development: organogenesis - part 2 of 3,0.0026,MYC|CTNNB1,29626,29736|29742,2.20E-04,,WP2839,0.284500737,0
183,3,WikiPathways,,Vitamin D receptor pathway,0.0026,CYP27B1|CDK2|MYC,29626,29718|29727|29736,2.20E-04,,WP2877,0.284500737,0
32,2,WikiPathways,,Nuclear receptors in lipid metabolism and toxicity,0.0026,CYP27B1|RARA,29626,29718|29739,2.20E-04,,WP299,0.284500737,0
31,2,WikiPathways,,miRNA regulation of prostate cancer signaling pathways,0.0026,GSK3B|CTNNB1,29626,29745|29742,2.10E-04,,WP3981,0.284500737,0
80,3,GO Biological Process,,Regulation of bone mineralization,0.0027,CYP27B1|SMAD3|RXRB,29626,29718|29715|29724,2.00E-05,,GO:0030500,0.282696854,0
81,3,GO Biological Process,,Endoderm development,0.0028,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,2.07E-05,,GO:0007492,0.280958581,0
195,3,KEGG Pathways,,Focal adhesion,0.0028,GSK3B|JUN|CTNNB1,29626,29745|29733|29742,2.70E-04,,hsa04510,0.280958581,0
192,3,KEGG Pathways,,Epstein-Barr virus infection,0.0028,CDK2|JUN|MYC,29626,29727|29733|29736,2.50E-04,,hsa05169,0.280958581,0
194,3,KEGG Pathways,,Proteoglycans in cancer,0.0028,SMAD2|MYC|CTNNB1,29626,29730|29736|29742,2.60E-04,,hsa05205,0.280958581,0
94,3,Reactome Pathways,,Transcriptional regulation by RUNX3,0.0028,SMAD3|MYC|CTNNB1,29626,29715|29736|29742,3.19E-05,,HSA-8878159,0.280958581,0
130,4,Monarch Phenotype,,Bruising susceptibility,0.0028,RARA|SMAD2|PRKCD|SMAD3,29626,29739|29730|29721|29715,1.39E-06,,HP:0000978,0.280958581,0
997,6,GO Biological Process,,Animal organ morphogenesis,0.0029,RARA|SMAD2|SMAD3|JUN|MYC|CTNNB1,29626,29739|29730|29715|29733|29736|29742,2.15E-05,,GO:0009887,0.279281314,0
565,5,GO Biological Process,,Tissue morphogenesis,0.0029,RARA|SMAD2|SMAD3|MYC|CTNNB1,29626,29739|29730|29715|29736|29742,2.11E-05,,GO:0048729,0.279281314,0
1931,8,GO Molecular Function,,Transcription regulator activity,0.0029,RARA|SMAD2|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29715|29748|29733|29724|29736|29742,7.07E-06,,GO:0140110,0.279281314,0
3085,9,GO Biological Process,,Regulation of molecular function,0.003,CYP27B1|RARA|SMAD2|GSK3B|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29718|29739|29730|29745|29721|29715|29733|29736|29742,2.23E-05,,GO:0065009,0.277660913,0
195,3,WikiPathways,,Focal adhesion,0.003,GSK3B|JUN|CTNNB1,29626,29745|29733|29742,2.70E-04,,WP306,0.277660913,0
35,2,WikiPathways,,Influence of laminopathies on Wnt signaling,0.003,GSK3B|CTNNB1,29626,29745|29742,2.60E-04,,WP4844,0.277660913,0
1587,7,GO Biological Process,,Positive regulation of molecular function,0.0032,CYP27B1|RARA|GSK3B|PRKCD|SMAD3|MYC|CTNNB1,29626,29718|29739|29745|29721|29715|29736|29742,2.48E-05,,GO:0044093,0.274576151,0
37,2,WikiPathways,,Nuclear receptors,0.0032,RARA|RXRB,29626,29739|29724,2.90E-04,,WP170,0.274576151,0
37,2,WikiPathways,,Neovascularisation processes,0.0032,SMAD2|SMAD3,29626,29730|29715,2.90E-04,,WP4331,0.274576151,0
209,3,KEGG Pathways,,Salmonella infection,0.0033,JUN|MYC|CTNNB1,29626,29733|29736|29742,3.20E-04,,hsa05132,0.273105351,0
590,5,GO Biological Process,,Positive regulation of cell death,0.0034,GSK3B|PRKCD|JUN|MYC|CTNNB1,29626,29745|29721|29733|29736|29742,2.59E-05,,GO:0010942,0.271678463,0
1035,6,GO Biological Process,,Negative regulation of multicellular organismal process,0.0034,RARA|GSK3B|PRKCD|SMAD3|MYC|CTNNB1,29626,29739|29745|29721|29715|29736|29742,2.66E-05,,GO:0051241,0.271678463,0
1041,6,GO Biological Process,,Apoptotic process,0.0035,GSK3B|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29745|29721|29715|29733|29736|29742,2.75E-05,,GO:0006915,0.270292939,0
89,3,GO Biological Process,,Regulation of fibroblast proliferation,0.0035,JUN|MYC|CTNNB1,29626,29733|29736|29742,2.72E-05,,GO:0048145,0.270292939,0
1038,6,GO Biological Process,,Negative regulation of protein metabolic process,0.0035,RARA|GSK3B|PRKCD|SMAD3|JUN|CTNNB1,29626,29739|29745|29721|29715|29733|29742,2.71E-05,,GO:0051248,0.270292939,0
1368,7,GO Molecular Function,,"DNA-binding transcription factor activity, RNA polymerase II-specific",0.0035,RARA|SMAD2|SMAD3|MYB|JUN|RXRB|MYC,29626,29739|29730|29715|29748|29733|29724|29736,9.34E-06,,GO:0000981,0.270292939,0
1318,7,TISSUES,,Fetus,0.0035,SMAD2|CDK2|GSK3B|SMAD3|MYB|MYC|CTNNB1,29626,29730|29727|29745|29715|29748|29736|29742,7.31E-06,,BTO:0000449,0.270292939,0
218,3,KEGG Pathways,,Shigellosis,0.0036,GSK3B|PRKCD|JUN,29626,29745|29721|29733,3.70E-04,,hsa05131,0.268946449,0
217,3,KEGG Pathways,,Human cytomegalovirus infection,0.0036,GSK3B|MYC|CTNNB1,29626,29745|29736|29742,3.60E-04,,hsa05163,0.268946449,0
40,2,WikiPathways,,ATM signaling pathway,0.0036,CDK2|JUN,29626,29727|29733,3.40E-04,,WP2516,0.268946449,0
1057,6,GO Biological Process,,Cellular response to oxygen-containing compound,0.0037,RARA|CDK2|GSK3B|PRKCD|JUN|CTNNB1,29626,29739|29727|29745|29721|29733|29742,3.00E-05,,GO:1901701,0.267636854,0
105,3,Reactome Pathways,,KEAP1-NFE2L2 pathway,0.0037,GSK3B|PRKCD|MYC,29626,29745|29721|29736,4.40E-05,,HSA-9755511,0.267636854,0
11,2,GO Biological Process,,Dorsal/ventral axis specification,0.0038,SMAD2|CTNNB1,29626,29730|29742,3.12E-05,,GO:0009950,0.266362186,0
11,2,GO Biological Process,,Nodal signaling pathway,0.0038,SMAD2|SMAD3,29626,29730|29715,3.12E-05,,GO:0038092,0.266362186,0
11,2,GO Biological Process,,Paraxial mesoderm morphogenesis,0.0038,SMAD2|SMAD3,29626,29730|29715,3.12E-05,,GO:0048340,0.266362186,0
1069,6,GO Biological Process,,Epithelium development,0.0038,RARA|SMAD2|SMAD3|JUN|MYC|CTNNB1,29626,29739|29730|29715|29733|29736|29742,3.20E-05,,GO:0060429,0.266362186,0
96,3,GO Biological Process,,Transforming growth factor beta receptor signaling pathway,0.0039,SMAD2|SMAD3|JUN,29626,29730|29715|29733,3.39E-05,,GO:0007179,0.26512063,0
3246,9,GO Biological Process,,Animal organ development,0.0039,CYP27B1|RARA|SMAD2|GSK3B|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29718|29739|29730|29745|29715|29748|29733|29736|29742,3.41E-05,,GO:0048513,0.26512063,0
95,3,GO Biological Process,,Embryonic skeletal system morphogenesis,0.0039,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,3.29E-05,,GO:0048704,0.26512063,0
225,4,UniProt Keywords,,Proto-oncogene,0.0039,RARA|MYB|JUN|MYC,29626,29739|29748|29733|29736,1.17E-05,,KW-0656,0.26512063,0
42,2,WikiPathways,,IL-2 signaling pathway,0.0039,JUN|MYC,29626,29733|29736,3.70E-04,,WP49,0.26512063,0
6,2,GO Molecular Function,,Retinoic acid-responsive element binding,0.004,RARA|RXRB,29626,29739|29724,1.12E-05,,GO:0044323,0.263910509,0
356,5,Monarch Phenotype,,Pain,0.004,RARA|SMAD2|SMAD3|MYC|CTNNB1,29626,29739|29730|29715|29736|29742,2.29E-06,,EFO:0003843,0.263910509,0
8,2,COMPARTMENTS,,Myb complex,0.0041,MYB|MYC,29626,29748|29736,1.80E-05,,GOCC:0031523,0.26273027,0
43,2,WikiPathways,,IL6 signaling pathway,0.0041,GSK3B|PRKCD,29626,29745|29721,3.90E-04,,WP364,0.26273027,0
43,2,WikiPathways,,Inflammatory bowel disease signaling,0.0041,SMAD2|JUN,29626,29730|29733,3.90E-04,,WP5198,0.26273027,0
43,2,WikiPathways,,Vitamin A and carotenoid metabolism,0.0041,RARA|RXRB,29626,29739|29724,3.90E-04,,WP716,0.26273027,0
641,5,GO Biological Process,,Enzyme-linked receptor protein signaling pathway,0.0042,SMAD2|GSK3B|SMAD3|JUN|CTNNB1,29626,29730|29745|29715|29733|29742,3.85E-05,,GO:0007167,0.261578474,0
304,4,GO Biological Process,,Positive regulation of DNA metabolic process,0.0042,CDK2|PRKCD|MYC|CTNNB1,29626,29727|29721|29736|29742,3.74E-05,,GO:0051054,0.261578474,0
637,5,GO Biological Process,,Cellular response to nitrogen compound,0.0042,CDK2|GSK3B|PRKCD|JUN|CTNNB1,29626,29727|29745|29721|29733|29742,3.74E-05,,GO:1901699,0.261578474,0
45,2,WikiPathways,,Aryl hydrocarbon receptor pathway,0.0043,CDK2|MYC,29626,29727|29736,4.30E-04,,WP2586,0.260453782,0
15,2,Reactome Pathways,,Signaling by Activin,0.0044,SMAD2|SMAD3,29626,29730|29715,5.43E-05,,HSA-1502540,0.259354947,0
17,2,Reactome Pathways,,Beta-catenin phosphorylation cascade,0.0044,GSK3B|CTNNB1,29626,29745|29742,6.82E-05,,HSA-196299,0.259354947,0
15,2,Reactome Pathways,,Signaling by GSK3beta mutants,0.0044,GSK3B|CTNNB1,29626,29745|29742,5.43E-05,,HSA-5339716,0.259354947,0
15,2,Reactome Pathways,,CTNNB1 S33 mutants arent phosphorylated,0.0044,GSK3B|CTNNB1,29626,29745|29742,5.43E-05,,HSA-5358747,0.259354947,0
15,2,Reactome Pathways,,CTNNB1 S37 mutants arent phosphorylated,0.0044,GSK3B|CTNNB1,29626,29745|29742,5.43E-05,,HSA-5358749,0.259354947,0
15,2,Reactome Pathways,,CTNNB1 S45 mutants arent phosphorylated,0.0044,GSK3B|CTNNB1,29626,29745|29742,5.43E-05,,HSA-5358751,0.259354947,0
15,2,Reactome Pathways,,CTNNB1 T41 mutants arent phosphorylated,0.0044,GSK3B|CTNNB1,29626,29745|29742,5.43E-05,,HSA-5358752,0.259354947,0
119,3,Reactome Pathways,,Estrogen-dependent gene expression,0.0044,MYB|JUN|MYC,29626,29748|29733|29736,6.32E-05,,HSA-9018519,0.259354947,0
17,2,Reactome Pathways,,FOXO-mediated transcription of cell cycle genes,0.0044,SMAD2|SMAD3,29626,29730|29715,6.82E-05,,HSA-9617828,0.259354947,0
46,2,WikiPathways,,Envelope proteins and their potential roles in EDMD physiopathology,0.0044,SMAD2|SMAD3,29626,29730|29715,4.50E-04,,WP4535,0.259354947,0
13,2,GO Biological Process,,Primary miRNA processing,0.0045,SMAD2|SMAD3,29626,29730|29715,4.20E-05,,GO:0031053,0.258280807,0
244,4,TISSUES,,Erythroleukemia cell,0.0045,GSK3B|MYB|JUN|MYC,29626,29745|29748|29733|29736,1.60E-05,,BTO:0000426,0.258280807,0
222,4,TISSUES,,Chronic lymphocytic leukemia cell,0.0045,CDK2|GSK3B|JUN|CTNNB1,29626,29727|29745|29733|29742,1.11E-05,,BTO:0001546,0.258280807,0
7,2,TISSUES,,Colorectal cancer cell,0.0045,MYC|CTNNB1,29626,29736|29742,1.44E-05,,BTO:0001615,0.258280807,0
6,2,TISSUES,,Myofibroblast,0.0045,SMAD2|SMAD3,29626,29730|29715,1.12E-05,,BTO:0001946,0.258280807,0
315,4,GO Biological Process,,Epithelial tube morphogenesis,0.0046,RARA|SMAD3|MYC|CTNNB1,29626,29739|29715|29736|29742,4.29E-05,,GO:0060562,0.257230276,0
315,4,GO Biological Process,,Regulation of leukocyte differentiation,0.0046,RARA|MYB|MYC|CTNNB1,29626,29739|29748|29736|29742,4.29E-05,,GO:1902105,0.257230276,0
77,3,GO Cellular Component,,Transcription repressor complex,0.0046,JUN|MYC|CTNNB1,29626,29733|29736|29742,1.79E-05,,GO:0017053,0.257230276,0
8,2,GO Cellular Component,,Heteromeric SMAD protein complex,0.0046,SMAD2|SMAD3,29626,29730|29715,1.80E-05,,GO:0071144,0.257230276,0
978,7,DISEASES,,Cancer,0.0046,RARA|CDK2|PRKCD|MYB|JUN|MYC|CTNNB1,29626,29739|29727|29721|29748|29733|29736|29742,1.00E-06,,DOID:162,0.257230276,0
241,3,KEGG Pathways,,Endocytosis,0.0046,SMAD2|SMAD3|WWP1,29626,29730|29715|29751,4.90E-04,,hsa04144,0.257230276,0
3355,9,GO Biological Process,,Regulation of cell communication,0.0047,CYP27B1|RARA|SMAD2|GSK3B|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29718|29739|29730|29745|29721|29715|29733|29736|29742,4.48E-05,,GO:0010646,0.256202339,0
318,4,GO Biological Process,,Apoptotic signaling pathway,0.0047,GSK3B|PRKCD|SMAD3|CTNNB1,29626,29745|29721|29715|29742,4.45E-05,,GO:0097190,0.256202339,0
747,5,Reactome Pathways,,Cellular responses to stress,0.0047,CDK2|GSK3B|PRKCD|JUN|MYC,29626,29727|29745|29721|29733|29736,7.95E-05,,HSA-2262752,0.256202339,0
1146,6,GO Biological Process,,Positive regulation of gene expression,0.0048,RARA|SMAD2|GSK3B|SMAD3|MYC|CTNNB1,29626,29739|29730|29745|29715|29736|29742,4.73E-05,,GO:0010628,0.255196044,0
3367,9,GO Biological Process,,Regulation of signaling,0.0048,CYP27B1|RARA|SMAD2|GSK3B|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29718|29739|29730|29745|29721|29715|29733|29736|29742,4.62E-05,,GO:0023051,0.255196044,0
161,4,Monarch Phenotype,,Abnormality of bone marrow cell morphology,0.0049,RARA|PRKCD|MYC|CTNNB1,29626,29739|29721|29736|29742,3.19E-06,,HP:0005561,0.2542105,0
245,3,WikiPathways,,MAPK signaling pathway,0.005,PRKCD|JUN|MYC,29626,29721|29733|29736,5.10E-04,,WP382,0.253244866,0
111,3,GO Biological Process,,Response to retinoic acid,0.0052,RARA|GSK3B|RXRB,29626,29739|29745|29724,5.17E-05,,GO:0032526,0.251370225,0
51,2,WikiPathways,,Copper homeostasis,0.0052,GSK3B|JUN,29626,29745|29733,5.40E-04,,WP3286,0.251370225,0
334,4,GO Biological Process,,Camera-type eye development,0.0053,RARA|SMAD3|JUN|CTNNB1,29626,29739|29715|29733|29742,5.37E-05,,GO:0043010,0.250459774,0
113,3,GO Biological Process,,Limbic system development,0.0054,RARA|GSK3B|CTNNB1,29626,29739|29745|29742,5.44E-05,,GO:0021761,0.249566342,0
1190,6,GO Biological Process,,Regulation of organelle organization,0.0057,CDK2|GSK3B|PRKCD|SMAD3|MYC|CTNNB1,29626,29727|29745|29721|29715|29736|29742,5.84E-05,,GO:0033043,0.246982079,0
1191,6,GO Biological Process,,Positive regulation of catalytic activity,0.0057,CYP27B1|GSK3B|PRKCD|SMAD3|MYC|CTNNB1,29626,29718|29745|29721|29715|29736|29742,5.87E-05,,GO:0043085,0.246982079,0
11,2,GO Cellular Component,,Beta-catenin destruction complex,0.0058,GSK3B|CTNNB1,29626,29745|29742,3.12E-05,,GO:0030877,0.246150802,0
2299,8,UniProt Keywords,,Transcription regulation,0.0058,RARA|SMAD2|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29739|29730|29715|29748|29733|29724|29736|29742,2.60E-05,,KW-0805,0.246150802,0
2399,8,UniProt Keywords,,Ubl conjugation,0.0058,RARA|SMAD2|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29739|29730|29715|29748|29733|29751|29736|29742,3.56E-05,,KW-0832,0.246150802,0
5506,11,GO Cellular Component,,Protein-containing complex,0.006,RARA|SMAD2|CDK2|GSK3B|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29715|29748|29733|29724|29751|29736|29742,3.54E-05,,GO:0032991,0.244530402,0
119,3,GO Biological Process,,Formation of primary germ layer,0.0061,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,6.32E-05,,GO:0001704,0.243740347,0
584,5,GO Molecular Function,,Chromatin binding,0.0061,RARA|SMAD2|SMAD3|JUN|CTNNB1,29626,29739|29730|29715|29733|29742,2.47E-05,,GO:0003682,0.243740347,0
22,2,Reactome Pathways,,Signaling by NODAL,0.0061,SMAD2|SMAD3,29626,29730|29715,1.10E-04,,HSA-1181150,0.243740347,0
89,3,GO Molecular Function,,Beta-catenin binding,0.0064,GSK3B|SMAD3|CTNNB1,29626,29745|29715|29742,2.72E-05,,GO:0008013,0.24144564,0
57,2,WikiPathways,,Neurogenesis regulation in the olfactory epithelium,0.0064,GSK3B|MYC,29626,29745|29736,6.70E-04,,WP5265,0.24144564,0
13,2,GO Cellular Component,,Wnt signalosome,0.0066,GSK3B|CTNNB1,29626,29745|29742,4.20E-05,,GO:1990909,0.23997484,0
59,2,WikiPathways,,Markers of kidney cell lineage,0.0068,RARA|CTNNB1,29626,29739|29742,7.20E-04,,WP5236,0.238547951,0
15,2,GO Cellular Component,,RNA polymerase II transcription repressor complex,0.0069,MYC|CTNNB1,29626,29736|29742,5.43E-05,,GO:0090571,0.237850169,0
60,2,WikiPathways,,Development of ureteric collection system,0.0069,RARA|CTNNB1,29626,29739|29742,7.40E-04,,WP5053,0.237850169,0
736,5,GO Biological Process,,Protein phosphorylation,0.007,RARA|SMAD2|CDK2|GSK3B|PRKCD,29626,29739|29730|29727|29745|29721,7.41E-05,,GO:0006468,0.237162427,0
11,2,GO Molecular Function,,co-SMAD binding,0.007,SMAD2|SMAD3,29626,29730|29715,3.12E-05,,GO:0070410,0.237162427,0
61,2,WikiPathways,,Notch signaling pathway,0.007,GSK3B|MYC,29626,29745|29736,7.70E-04,,WP61,0.237162427,0
1246,6,GO Biological Process,,Cell cycle,0.0071,CYP27B1|CDK2|PRKCD|MYB|MYC|CTNNB1,29626,29718|29727|29721|29748|29736|29742,7.55E-05,,GO:0007049,0.236484441,0
18,2,GO Biological Process,,Retinoic acid receptor signaling pathway,0.0071,RARA|RXRB,29626,29739|29724,7.58E-05,,GO:0048384,0.236484441,0
366,4,GO Biological Process,,Regulation of epithelial cell proliferation,0.0071,SMAD3|JUN|MYC|CTNNB1,29626,29715|29733|29736|29742,7.64E-05,,GO:0050678,0.236484441,0
365,4,GO Biological Process,,Regulation of apoptotic signaling pathway,0.0071,GSK3B|PRKCD|MYC|CTNNB1,29626,29745|29721|29736|29742,7.56E-05,,GO:2001233,0.236484441,0
299,4,GO Molecular Function,,Ubiquitin protein ligase binding,0.0071,SMAD2|GSK3B|SMAD3|JUN,29626,29730|29745|29715|29733,3.51E-05,,GO:0031625,0.236484441,0
62,2,WikiPathways,,T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection,0.0072,GSK3B|JUN,29626,29745|29733,7.90E-04,,WP3863,0.235815937,0
63,2,KEGG Pathways,,Basal cell carcinoma,0.0074,GSK3B|CTNNB1,29626,29745|29742,8.20E-04,,hsa05217,0.234506342,0
64,2,WikiPathways,,Oncostatin M signaling pathway,0.0075,CDK2|PRKCD,29626,29727|29721,8.40E-04,,WP2374,0.233864759,0
65,2,WikiPathways,,Pathways affected in adenoid cystic carcinoma,0.0075,MYB|MYC,29626,29748|29736,8.70E-04,,WP3651,0.233864759,0
64,2,WikiPathways,,G1 to S cell cycle control,0.0075,CDK2|MYC,29626,29727|29736,8.40E-04,,WP45,0.233864759,0
64,2,WikiPathways,,3q29 copy number variation syndrome,0.0075,JUN|MYC,29626,29733|29736,8.40E-04,,WP4906,0.233864759,0
12,2,COMPARTMENTS,,Beta-catenin destruction complex,0.0076,GSK3B|CTNNB1,29626,29745|29742,3.64E-05,,GOCC:0030877,0.233231674,0
9083,13,COMPARTMENTS,,Membrane-bounded organelle,0.0076,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29715|29748|29733|29724|29751|29736|29742,4.28E-05,,GOCC:0043227,0.233231674,0
3309,9,COMPARTMENTS,,Intracellular non-membrane-bounded organelle,0.0076,RARA|SMAD2|CDK2|GSK3B|SMAD3|MYB|JUN|MYC|CTNNB1,29626,29739|29730|29727|29745|29715|29748|29733|29736|29742,4.00E-05,,GOCC:0043232,0.233231674,0
12,2,COMPARTMENTS,,Wnt signalosome,0.0076,GSK3B|CTNNB1,29626,29745|29742,3.64E-05,,GOCC:1990909,0.233231674,0
131,3,GO Biological Process,,Liver development,0.0077,RARA|SMAD3|JUN,29626,29739|29715|29733,8.36E-05,,GO:0001889,0.232606865,0
19,2,GO Biological Process,,Pericardium development,0.0077,SMAD2|SMAD3,29626,29730|29715,8.37E-05,,GO:0060039,0.232606865,0
19,2,GO Biological Process,,Trachea development,0.0077,RARA|CTNNB1,29626,29739|29742,8.37E-05,,GO:0060438,0.232606865,0
762,5,GO Biological Process,,Response to hormone,0.0078,CYP27B1|RARA|GSK3B|PRKCD|RXRB,29626,29718|29739|29745|29721|29724,8.73E-05,,GO:0009725,0.231990118,0
133,3,GO Biological Process,,Regulation of dephosphorylation,0.0078,GSK3B|PRKCD|SMAD3,29626,29745|29721|29715,8.73E-05,,GO:0035303,0.231990118,0
3654,9,GO Biological Process,,Regulation of biological quality,0.0079,CYP27B1|RARA|SMAD2|GSK3B|PRKCD|SMAD3|MYB|MYC|CTNNB1,29626,29718|29739|29730|29745|29721|29715|29748|29736|29742,9.05E-05,,GO:0065008,0.231381228,0
67,2,KEGG Pathways,,Acute myeloid leukemia,0.0081,RARA|MYC,29626,29739|29736,9.20E-04,,hsa05221,0.230186235,0
68,2,WikiPathways,,RAC1/PAK1/p38/MMP2 pathway,0.0081,MYC|CTNNB1,29626,29736|29742,9.50E-04,,WP3303,0.230186235,0
26,2,Reactome Pathways,,Downregulation of TGF-beta receptor signaling,0.0082,SMAD2|SMAD3,29626,29730|29715,1.50E-04,,HSA-2173788,0.229599759,0
162,3,Reactome Pathways,,S Phase,0.0082,CDK2|GSK3B|MYC,29626,29727|29745|29736,1.50E-04,,HSA-69242,0.229599759,0
69,2,WikiPathways,,DNA damage response,0.0083,CDK2|MYC,29626,29727|29736,9.70E-04,,WP707,0.229020391,0
69,2,KEGG Pathways,,Adherens junction,0.0084,SMAD3|CTNNB1,29626,29715|29742,9.70E-04,,hsa04520,0.228447963,0
27,2,Reactome Pathways,,G0 and Early G1,0.0084,CDK2|MYC,29626,29727|29736,1.60E-04,,HSA-1538133,0.228447963,0
784,5,GO Biological Process,,Regulation of cell adhesion,0.0086,RARA|GSK3B|PRKCD|SMAD3|MYB,29626,29739|29745|29721|29715|29748,9.98E-05,,GO:0030155,0.22732327,0
71,2,KEGG Pathways,,Pancreatic cancer,0.0086,SMAD2|SMAD3,29626,29730|29715,0.001,,hsa05212,0.22732327,0
71,2,WikiPathways,,miRNA regulation of DNA damage response,0.0086,CDK2|MYC,29626,29727|29736,0.001,,WP1530,0.22732327,0
143,3,GO Biological Process,,Regulation of protein localization to nucleus,0.0091,GSK3B|PRKCD|SMAD3,29626,29745|29721|29715,1.10E-04,,GO:1900180,0.224622143,0
22,2,GO Biological Process,,Positive regulation of T-helper cell differentiation,0.0093,RARA|MYB,29626,29739|29748,1.10E-04,,GO:0045624,0.223583032,0
324,3,KEGG Pathways,,Human papillomavirus infection,0.0094,CDK2|GSK3B|CTNNB1,29626,29727|29745|29742,0.0011,,hsa05165,0.223071827,0
75,2,KEGG Pathways,,Chronic myeloid leukemia,0.0094,SMAD3|MYC,29626,29715|29736,0.0011,,hsa05220,0.223071827,0
29,2,Reactome Pathways,,Downregulation of SMAD2/3:SMAD4 transcriptional activity,0.0094,SMAD2|SMAD3,29626,29730|29715,1.80E-04,,HSA-2173795,0.223071827,0
78,2,KEGG Pathways,,B cell receptor signaling pathway,0.0096,GSK3B|JUN,29626,29745|29733,0.0012,,hsa04662,0.222065533,0
333,4,GO Molecular Function,,DNA-binding transcription repressor activity,0.0097,RARA|SMAD3|JUN|MYC,29626,29739|29715|29733|29736,5.31E-05,,GO:0001217,0.22157022,0
30,2,Reactome Pathways,,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",0.0098,SMAD2|SMAD3,29626,29730|29715,2.00E-04,,HSA-9615017,0.221079988,0
23,2,GO Biological Process,,Positive regulation of mesenchymal cell proliferation,0.01,MYC|CTNNB1,29626,29736|29742,1.20E-04,,GO:0002053,0.220114355,0
3785,9,GO Biological Process,,Transport,0.01,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29751|29736|29742,1.20E-04,,GO:0006810,0.220114355,0
23,2,GO Biological Process,,Signal transduction involved in regulation of gene expression,0.01,SMAD2|SMAD3,29626,29730|29715,1.20E-04,,GO:0023019,0.220114355,0
412,4,GO Biological Process,,Developmental growth,0.01,RARA|SMAD2|SMAD3|CTNNB1,29626,29739|29730|29715|29742,1.20E-04,,GO:0048589,0.220114355,0
31,2,Reactome Pathways,,Disassembly of the destruction complex and recruitment of AXIN to the membrane,0.0102,GSK3B|CTNNB1,29626,29745|29742,2.10E-04,,HSA-4641262,0.219167844,0
702,5,GO Molecular Function,,Protein kinase binding,0.0104,RARA|GSK3B|PRKCD|SMAD3|CTNNB1,29626,29739|29745|29721|29715|29742,5.93E-05,,GO:0019901,0.218239713,0
7835,12,GO Biological Process,,Response to stimulus,0.0105,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29715|29733|29724|29751|29736|29742,1.30E-04,,GO:0050896,0.21778232,0
349,3,KEGG Pathways,,PI3K-Akt signaling pathway,0.0108,CDK2|GSK3B|MYC,29626,29727|29745|29736,0.0014,,hsa04151,0.21643583,0
1971,7,UniProt Keywords,,DNA-binding,0.0113,RARA|SMAD2|SMAD3|MYB|JUN|RXRB|MYC,29626,29739|29730|29715|29748|29733|29724|29736,1.00E-04,,KW-0238,0.214272691,0
82,2,WikiPathways,,Glioblastoma signaling pathways,0.0113,CDK2|PRKCD,29626,29727|29721,0.0014,,WP2261,0.214272691,0
87,2,KEGG Pathways,,GnRH signaling pathway,0.0114,PRKCD|JUN,29626,29721|29733,0.0015,,hsa04912,0.213851567,0
83,2,WikiPathways,,MicroRNAs in cardiomyocyte hypertrophy,0.0114,GSK3B|CTNNB1,29626,29745|29742,0.0014,,WP1544,0.213851567,0
83,2,WikiPathways,,Apoptosis,0.0114,JUN|MYC,29626,29733|29736,0.0014,,WP254,0.213851567,0
83,2,WikiPathways,,EGFR tyrosine kinase inhibitor resistance,0.0114,GSK3B|MYC,29626,29745|29736,0.0014,,WP4806,0.213851567,0
7672,12,GO Cellular Component,,Nucleus,0.0116,RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29721|29715|29748|29733|29724|29751|29736|29742,1.00E-04,,GO:0005634,0.21302029,0
26,2,GO Biological Process,,Response to muscle stretch,0.012,JUN|CTNNB1,29626,29733|29742,1.50E-04,,GO:0035994,0.21139989,0
160,3,GO Biological Process,,Positive regulation of intracellular protein transport,0.012,GSK3B|PRKCD|SMAD3,29626,29745|29721|29715,1.50E-04,,GO:0090316,0.21139989,0
91,2,KEGG Pathways,,IL-17 signaling pathway,0.0121,GSK3B|JUN,29626,29745|29733,0.0017,,hsa04657,0.21100323,0
87,2,WikiPathways,,Retinoblastoma gene in cancer,0.0121,CDK2|MYC,29626,29727|29736,0.0015,,WP2446,0.21100323,0
87,2,WikiPathways,,Hair follicle development: cytodifferentiation - part 3 of 3,0.0121,JUN|CTNNB1,29626,29733|29742,0.0015,,WP2840,0.21100323,0
88,2,WikiPathways,,T-cell activation SARS-CoV-2,0.0122,GSK3B|JUN,29626,29745|29733,0.0016,,WP5098,0.210609835,0
20,2,COMPARTMENTS,,Transforming growth factor beta complex,0.0125,SMAD2|SMAD3,29626,29730|29715,9.21E-05,,GOCC:0099126,0.209448712,0
164,3,GO Biological Process,,Negative regulation of binding,0.0126,GSK3B|PRKCD|JUN,29626,29745|29721|29733,1.60E-04,,GO:0051100,0.209067856,0
90,2,WikiPathways,,T-cell receptor signaling pathway,0.0126,PRKCD|JUN,29626,29721|29733,0.0016,,WP69,0.209067856,0
27,2,GO Biological Process,,Adrenal gland development,0.0127,SMAD2|SMAD3,29626,29730|29715,1.60E-04,,GO:0030325,0.20869001,0
27,2,GO Biological Process,,Positive regulation of histone H3-K4 methylation,0.0127,MYB|CTNNB1,29626,29748|29742,1.60E-04,,GO:0051571,0.20869001,0
95,2,KEGG Pathways,,Melanogenesis,0.0129,GSK3B|CTNNB1,29626,29745|29742,0.0018,,hsa04916,0.207943163,0
1438,6,GO Biological Process,,Regulation of immune system process,0.013,RARA|PRKCD|SMAD3|MYB|MYC|CTNNB1,29626,29739|29721|29715|29748|29736|29742,1.70E-04,,GO:0002682,0.207574071,0
38,2,Reactome Pathways,,Apoptotic cleavage of cellular proteins,0.013,PRKCD|CTNNB1,29626,29721|29742,3.10E-04,,HSA-111465,0.207574071,0
204,3,Reactome Pathways,,Signaling by NOTCH,0.013,SMAD3|JUN|MYC,29626,29715|29733|29736,3.00E-04,,HSA-157118,0.207574071,0
201,3,Reactome Pathways,,TCF dependent signaling in response to WNT,0.013,GSK3B|MYC|CTNNB1,29626,29745|29736|29742,2.90E-04,,HSA-201681,0.207574071,0
203,3,Reactome Pathways,,Ub-specific processing proteases,0.013,SMAD2|SMAD3|MYC,29626,29730|29715|29736,3.00E-04,,HSA-5689880,0.207574071,0
521,4,Reactome Pathways,,Signaling by Receptor Tyrosine Kinases,0.013,PRKCD|WWP1|MYC|CTNNB1,29626,29721|29751|29736|29742,2.90E-04,,HSA-9006934,0.207574071,0
2978,8,GO Biological Process,,Regulation of signal transduction,0.0132,CYP27B1|SMAD2|GSK3B|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29718|29730|29745|29721|29715|29733|29736|29742,1.70E-04,,GO:0009966,0.206844328,0
454,4,GO Biological Process,,Embryonic organ development,0.0132,RARA|SMAD2|SMAD3|CTNNB1,29626,29739|29730|29715|29742,1.70E-04,,GO:0048568,0.206844328,0
97,2,KEGG Pathways,,Chagas disease,0.0132,SMAD2|JUN,29626,29730|29733,0.0019,,hsa05142,0.206844328,0
93,2,WikiPathways,,Thyroid hormones production and peripheral downstream signaling effects,0.0133,GSK3B|CTNNB1,29626,29745|29742,0.0017,,WP4746,0.206483593,0
101,2,KEGG Pathways,,C-type lectin receptor signaling pathway,0.0137,PRKCD|JUN,29626,29721|29733,0.002,,hsa04625,0.205067275,0
100,2,KEGG Pathways,,T cell receptor signaling pathway,0.0137,GSK3B|JUN,29626,29745|29733,0.002,,hsa04660,0.205067275,0
5977,11,GO Molecular Function,,Heterocyclic compound binding,0.014,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC,29626,29718|29739|29730|29727|29745|29721|29715|29748|29733|29724|29736,8.22E-05,,GO:1901363,0.204031916,0
899,5,GO Biological Process,,Negative regulation of gene expression,0.0142,RARA|SMAD2|GSK3B|SMAD3|CTNNB1,29626,29739|29730|29745|29715|29742,1.90E-04,,GO:0010629,0.203353929,0
104,2,KEGG Pathways,,"Parathyroid hormone synthesis, secretion and action",0.0142,CYP27B1|RXRB,29626,29718|29724,0.0021,,hsa04928,0.203353929,0
106,2,KEGG Pathways,,Insulin resistance,0.0144,GSK3B|PRKCD,29626,29745|29721,0.0022,,hsa04931,0.202685426,0
30,2,GO Biological Process,,Negative regulation of cartilage development,0.0146,RARA|CTNNB1,29626,29739|29742,2.00E-04,,GO:0061037,0.202026143,0
8,2,SMART Domains,,Domain B in dwarfin family proteins,0.0148,SMAD2|SMAD3,29626,29730|29715,1.80E-05,,SM00524,0.201375831,0
12,2,SMART Domains,,Domain A in dwarfin family proteins,0.0149,SMAD2|SMAD3,29626,29730|29715,3.64E-05,,SM00523,0.201053963,0
1490,6,GO Biological Process,,Biological process involved in interspecies interaction between organisms,0.015,CYP27B1|RARA|PRKCD|SMAD3|JUN|WWP1,29626,29718|29739|29721|29715|29733|29751,2.00E-04,,GO:0044419,0.200734248,0
473,4,GO Biological Process,,Cellular response to growth factor stimulus,0.015,SMAD2|SMAD3|JUN|CTNNB1,29626,29730|29715|29733|29742,2.00E-04,,GO:0071363,0.200734248,0
179,3,GO Biological Process,,Pallium development,0.0151,RARA|GSK3B|CTNNB1,29626,29739|29745|29742,2.10E-04,,GO:0021543,0.200416657,0
6050,11,GO Molecular Function,,Organic cyclic compound binding,0.0153,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC,29626,29718|29739|29730|29727|29745|29721|29715|29748|29733|29724|29736,9.30E-05,,GO:0097159,0.199787737,0
181,3,GO Biological Process,,Positive regulation of binding,0.0155,RARA|GSK3B|CTNNB1,29626,29739|29745|29742,2.10E-04,,GO:0051099,0.199166985,0
6,2,DISEASES,,Renal fibrosis,0.0159,SMAD2|SMAD3,29626,29730|29715,1.12E-05,,DOID:0050855,0.197949156,0
6291,12,DISEASES,,Disease,0.0159,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29715|29748|29733|29751|29736|29742,1.04E-05,,DOID:4,0.197949156,0
43,2,Reactome Pathways,,Signaling by Retinoic Acid,0.0159,RARA|RXRB,29626,29739|29724,3.90E-04,,HSA-5362517,0.197949156,0
1512,6,GO Biological Process,,Positive regulation of protein metabolic process,0.016,GSK3B|PRKCD|SMAD3|MYB|MYC|CTNNB1,29626,29745|29721|29715|29748|29736|29742,2.20E-04,,GO:0051247,0.197649486,0
485,4,GO Biological Process,,Positive regulation of cell adhesion,0.0161,RARA|GSK3B|SMAD3|MYB,29626,29739|29745|29715|29748,2.20E-04,,GO:0045785,0.197351683,0
104,2,WikiPathways,,7q11.23 copy number variation syndrome,0.0163,MYC|CTNNB1,29626,29736|29742,0.0021,,WP4932,0.196761586,0
489,4,GO Biological Process,,Cellular response to hormone stimulus,0.0165,RARA|GSK3B|PRKCD|RXRB,29626,29739|29745|29721|29724,2.30E-04,,GO:0032870,0.196178686,0
938,5,GO Biological Process,,Anatomical structure formation involved in morphogenesis,0.0165,RARA|SMAD2|SMAD3|JUN|CTNNB1,29626,29739|29730|29715|29733|29742,2.30E-04,,GO:0048646,0.196178686,0
945,5,GO Biological Process,,Positive regulation of cell population proliferation,0.0169,RARA|CDK2|JUN|MYC|CTNNB1,29626,29739|29727|29733|29736|29742,2.40E-04,,GO:0008284,0.195033787,0
34,2,GO Biological Process,,Positive regulation of telomerase activity,0.0176,MYC|CTNNB1,29626,29736|29742,2.50E-04,,GO:0051973,0.193093923,0
73,3,Monarch Phenotype,,Bone pain,0.0176,CYP27B1|RARA|CTNNB1,29626,29718|29739|29742,1.53E-05,,HP:0002653,0.193093923,0
7,2,Monarch Phenotype,,Burkitt lymphoma,0.0176,PRKCD|MYC,29626,29721|29736,1.44E-05,,HP:0030080,0.193093923,0
73,3,Monarch Phenotype,,Chest pain,0.0176,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,1.53E-05,,HP:0100749,0.193093923,0
193,3,GO Biological Process,,Peptidyl-serine phosphorylation,0.0179,CDK2|GSK3B|PRKCD,29626,29727|29745|29721,2.60E-04,,GO:0018105,0.192286064,0
506,4,GO Biological Process,,Negative regulation of protein modification process,0.0182,GSK3B|PRKCD|JUN|CTNNB1,29626,29745|29721|29733|29742,2.60E-04,,GO:0031400,0.191491632,0
1244,6,TISSUES,,Placenta,0.0182,SMAD2|CDK2|GSK3B|SMAD3|MYC|CTNNB1,29626,29730|29727|29745|29715|29736|29742,7.49E-05,,BTO:0001078,0.191491632,0
508,4,GO Biological Process,,Positive regulation of organelle organization,0.0183,CDK2|GSK3B|SMAD3|CTNNB1,29626,29727|29745|29715|29742,2.70E-04,,GO:0010638,0.191229729,0
507,4,GO Biological Process,,Positive regulation of apoptotic process,0.0183,PRKCD|JUN|MYC|CTNNB1,29626,29721|29733|29736|29742,2.60E-04,,GO:0043065,0.191229729,0
1572,6,GO Biological Process,,Cellular response to stress,0.0186,CDK2|GSK3B|PRKCD|SMAD3|JUN|MYC,29626,29727|29745|29721|29715|29733|29736,2.70E-04,,GO:0033554,0.190452521,0
124,2,KEGG Pathways,,Yersinia infection,0.0191,GSK3B|JUN,29626,29745|29733,0.003,,hsa05135,0.189184616,0
518,4,GO Biological Process,,"Transcription, DNA-templated",0.0194,RARA|SMAD2|CDK2|CTNNB1,29626,29739|29730|29727|29742,2.90E-04,,GO:0006351,0.188439709,0
126,2,KEGG Pathways,,FoxO signaling pathway,0.0194,CDK2|SMAD3,29626,29727|29715,0.0031,,hsa04068,0.188439709,0
126,2,KEGG Pathways,,Relaxin signaling pathway,0.0194,SMAD2|JUN,29626,29730|29733,0.0031,,hsa04926,0.188439709,0
129,2,KEGG Pathways,,Fluid shear stress and atherosclerosis,0.0196,JUN|CTNNB1,29626,29733|29742,0.0033,,hsa05418,0.187949476,0
115,2,WikiPathways,,Spinal cord injury,0.0196,CDK2|MYC,29626,29727|29736,0.0026,,WP2431,0.187949476,0
24,2,GO Molecular Function,,Transforming growth factor beta receptor binding,0.0199,SMAD2|SMAD3,29626,29730|29715,1.30E-04,,GO:0005160,0.187223429,0
204,3,GO Biological Process,,Respiratory system development,0.0201,RARA|SMAD2|CTNNB1,29626,29739|29730|29742,3.00E-04,,GO:0060541,0.186745452,0
117,2,WikiPathways,,Osteoblast differentiation and related diseases,0.0201,PRKCD|CTNNB1,29626,29721|29742,0.0027,,WP4787,0.186745452,0
133,2,KEGG Pathways,,Apelin signaling pathway,0.0204,SMAD2|SMAD3,29626,29730|29715,0.0035,,hsa04371,0.186037332,0
119,2,WikiPathways,,Hippo-Merlin signaling dysregulation,0.0205,MYC|CTNNB1,29626,29736|29742,0.0028,,WP4541,0.185803605,0
207,3,GO Biological Process,,Positive regulation of epithelial cell proliferation,0.0207,JUN|MYC|CTNNB1,29626,29733|29736|29742,3.20E-04,,GO:0050679,0.18533955,0
2365,7,GO Biological Process,,Regulation of cellular component organization,0.0209,CYP27B1|CDK2|GSK3B|PRKCD|SMAD3|MYC|CTNNB1,29626,29718|29727|29745|29721|29715|29736|29742,3.20E-04,,GO:0051128,0.184879958,0
83,3,Monarch Phenotype,,Exertional dyspnea,0.0209,RARA|SMAD2|SMAD3,29626,29739|29730|29715,2.22E-05,,HP:0002875,0.184879958,0
2370,7,GO Biological Process,,Regulation of catalytic activity,0.021,CYP27B1|GSK3B|PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29718|29745|29721|29715|29733|29736|29742,3.30E-04,,GO:0050790,0.184651809,0
539,4,GO Biological Process,,Regulation of cellular macromolecule biosynthetic process,0.0215,RARA|GSK3B|MYC|CTNNB1,29626,29739|29745|29736|29742,3.30E-04,,GO:2000112,0.183527116,0
2084,7,GO Molecular Function,,Enzyme binding,0.0215,RARA|SMAD2|GSK3B|PRKCD|SMAD3|JUN|CTNNB1,29626,29739|29730|29745|29721|29715|29733|29742,1.40E-04,,GO:0019899,0.183527116,0
52,2,Reactome Pathways,,Nuclear Receptor transcription pathway,0.0222,RARA|RXRB,29626,29739|29724,5.60E-04,,HSA-383280,0.181995724,0
216,3,GO Biological Process,,Anterior/posterior pattern specification,0.0226,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,3.60E-04,,GO:0009952,0.181142179,0
41,2,GO Biological Process,,Regulation of hematopoietic progenitor cell differentiation,0.0226,RARA|MYB,29626,29739|29748,3.60E-04,,GO:1901532,0.181142179,0
219,3,GO Biological Process,,MAPK cascade,0.0233,SMAD3|MYC|CTNNB1,29626,29715|29736|29742,3.70E-04,,GO:0000165,0.179684199,0
42,2,GO Biological Process,,Positive regulation of protein import into nucleus,0.0233,PRKCD|SMAD3,29626,29721|29715,3.70E-04,,GO:0042307,0.179684199,0
219,3,GO Biological Process,,Negative regulation of neuron death,0.0233,GSK3B|JUN|CTNNB1,29626,29745|29733|29742,3.70E-04,,GO:1901215,0.179684199,0
275,4,DISEASES,,Kidney disease,0.0233,CYP27B1|SMAD2|SMAD3|CTNNB1,29626,29718|29730|29715|29742,2.54E-05,,DOID:557,0.179684199,0
146,2,KEGG Pathways,,Non-alcoholic fatty liver disease,0.024,GSK3B|JUN,29626,29745|29733,0.0041,,hsa04932,0.178269379,0
8162,12,COMPARTMENTS,,Intracellular membrane-bounded organelle,0.025,CYP27B1|RARA|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|MYC|CTNNB1,29626,29718|29739|29730|29727|29745|29721|29715|29748|29733|29724|29736|29742,2.10E-04,,GOCC:0043231,0.176318201,0
3358,8,GO Biological Process,,Response to stress,0.0251,CYP27B1|SMAD2|CDK2|GSK3B|PRKCD|SMAD3|JUN|MYC,29626,29718|29730|29727|29745|29721|29715|29733|29736,4.10E-04,,GO:0006950,0.176127393,0
44,2,GO Biological Process,,Positive regulation of bone mineralization,0.0251,SMAD3|RXRB,29626,29715|29724,4.10E-04,,GO:0030501,0.176127393,0
45,2,GO Biological Process,,Embryonic axis specification,0.0258,SMAD2|CTNNB1,29626,29730|29742,4.30E-04,,GO:0000578,0.174812652,0
45,2,GO Biological Process,,Branching involved in ureteric bud morphogenesis,0.0258,MYC|CTNNB1,29626,29736|29742,4.30E-04,,GO:0001658,0.174812652,0
574,4,GO Biological Process,,Leukocyte activation,0.0258,PRKCD|SMAD3|JUN|CTNNB1,29626,29721|29715|29733|29742,4.20E-04,,GO:0045321,0.174812652,0
574,4,GO Biological Process,,Cellular response to organonitrogen compound,0.0258,GSK3B|PRKCD|JUN|CTNNB1,29626,29745|29721|29733|29742,4.20E-04,,GO:0071417,0.174812652,0
135,2,WikiPathways,,Measles virus infection,0.026,CDK2|JUN,29626,29727|29733,0.0036,,WP4630,0.174443559,0
1719,6,GO Biological Process,,Cell development,0.0265,RARA|GSK3B|SMAD3|MYB|JUN|CTNNB1,29626,29739|29745|29715|29748|29733|29742,4.50E-04,,GO:0048468,0.173533108,0
46,2,GO Biological Process,,Embryonic cranial skeleton morphogenesis,0.0265,SMAD2|SMAD3,29626,29730|29715,4.50E-04,,GO:0048701,0.173533108,0
138,2,WikiPathways,,Ectoderm differentiation,0.0268,MYC|CTNNB1,29626,29736|29742,0.0037,,WP2858,0.172995048,0
140,2,WikiPathways,,Neuroinflammation and glutamatergic signaling,0.0273,SMAD2|SMAD3,29626,29730|29715,0.0038,,WP5083,0.172111525,0
589,4,GO Biological Process,,Positive regulation of hydrolase activity,0.0275,GSK3B|PRKCD|SMAD3|MYC,29626,29745|29721|29715|29736,4.70E-04,,GO:0051345,0.171762638,0
47,2,GO Biological Process,,Regulation of muscle tissue development,0.0275,SMAD3|CTNNB1,29626,29715|29742,4.60E-04,,GO:1901861,0.171762638,0
590,4,GO Biological Process,,Embryonic morphogenesis,0.0276,RARA|SMAD2|SMAD3|CTNNB1,29626,29739|29730|29715|29742,4.70E-04,,GO:0048598,0.171589146,0
48,2,GO Biological Process,,Prostate gland development,0.0283,RARA|CTNNB1,29626,29739|29742,4.80E-04,,GO:0030850,0.170392015,0
48,2,GO Biological Process,,Regulation of myelination,0.0283,RARA|CTNNB1,29626,29739|29742,4.80E-04,,GO:0031641,0.170392015,0
1107,5,GO Biological Process,,Response to abiotic stimulus,0.0289,PRKCD|SMAD3|JUN|MYC|CTNNB1,29626,29721|29715|29733|29736|29742,5.00E-04,,GO:0009628,0.169389239,0
1108,5,GO Biological Process,,Regulation of cell cycle,0.0289,RARA|CDK2|JUN|MYC|CTNNB1,29626,29739|29727|29733|29736|29742,5.00E-04,,GO:0051726,0.169389239,0
146,2,WikiPathways,,Mesodermal commitment pathway,0.0294,SMAD2|SMAD3,29626,29730|29715,0.0041,,WP2857,0.168569369,0
5325,10,COMPARTMENTS,,Protein-containing complex,0.0297,RARA|SMAD2|CDK2|GSK3B|SMAD3|MYB|JUN|WWP1|MYC|CTNNB1,29626,29739|29730|29727|29745|29715|29748|29733|29751|29736|29742,2.60E-04,,GOCC:0032991,0.168084114,0
1121,5,GO Biological Process,,Organic cyclic compound biosynthetic process,0.0303,CYP27B1|RARA|SMAD2|CDK2|CTNNB1,29626,29718|29739|29730|29727|29742,5.30E-04,,GO:1901362,0.167128138,0
250,3,GO Biological Process,,Cell fate commitment,0.031,RARA|SMAD2|CTNNB1,29626,29739|29730|29742,5.40E-04,,GO:0045165,0.166036474,0
251,3,GO Biological Process,,Regulation of canonical Wnt signaling pathway,0.031,GSK3B|SMAD3|CTNNB1,29626,29745|29715|29742,5.50E-04,,GO:0060828,0.166036474,0
3507,8,GO Biological Process,,Cell differentiation,0.0312,RARA|SMAD2|GSK3B|SMAD3|MYB|JUN|RXRB|CTNNB1,29626,29739|29730|29745|29715|29748|29733|29724|29742,5.50E-04,,GO:0030154,0.165729095,0
617,4,GO Biological Process,,Epithelial cell differentiation,0.0312,RARA|SMAD3|JUN|CTNNB1,29626,29739|29715|29733|29742,5.60E-04,,GO:0030855,0.165729095,0
252,3,GO Biological Process,,Response to alcohol,0.0312,RARA|SMAD2|CTNNB1,29626,29739|29730|29742,5.60E-04,,GO:0097305,0.165729095,0
253,3,GO Biological Process,,Regulation of chromosome organization,0.0313,CDK2|MYC|CTNNB1,29626,29727|29736|29742,5.60E-04,,GO:0033044,0.165576144,0
53,2,GO Biological Process,,Regulation of chondrocyte differentiation,0.0322,SMAD3|CTNNB1,29626,29715|29742,5.80E-04,,GO:0032330,0.164221171,0
154,2,WikiPathways,,Nonalcoholic fatty liver disease,0.0323,GSK3B|JUN,29626,29745|29733,0.0046,,WP4396,0.164072962,0
27,2,TISSUES,,Colonic adenocarcinoma cell line,0.0326,MYC|CTNNB1,29626,29736|29742,1.60E-04,,BTO:0001913,0.163631074,0
173,2,KEGG Pathways,,NOD-like receptor signaling pathway,0.0326,PRKCD|JUN,29626,29721|29733,0.0057,,hsa04621,0.163631074,0
706,4,Reactome Pathways,,Cytokine Signaling in Immune system,0.0328,PRKCD|SMAD3|JUN|MYC,29626,29721|29715|29733|29736,9.20E-04,,HSA-1280215,0.163338736,0
156,2,WikiPathways,,Myometrial relaxation and contraction pathways,0.0328,PRKCD|JUN,29626,29721|29733,0.0047,,WP289,0.163338736,0
54,2,GO Biological Process,,Endoderm formation,0.0332,SMAD2|CTNNB1,29626,29730|29742,6.10E-04,,GO:0001706,0.162759368,0
54,2,GO Biological Process,,Positive regulation of fibroblast proliferation,0.0332,JUN|MYC,29626,29733|29736,6.10E-04,,GO:0048146,0.162759368,0
1979,6,Reactome Pathways,,Immune System,0.0334,PRKCD|SMAD3|JUN|WWP1|MYC|CTNNB1,29626,29721|29715|29733|29751|29736|29742,9.50E-04,,HSA-168256,0.162472297,0
306,3,Reactome Pathways,,Intracellular signaling by second messengers,0.0336,GSK3B|PRKCD|JUN,29626,29745|29721|29733,9.70E-04,,HSA-9006925,0.162186939,0
263,3,GO Biological Process,,Myeloid cell differentiation,0.0337,MYB|JUN|CTNNB1,29626,29748|29733|29742,6.30E-04,,GO:0030099,0.162044897,0
162,2,WikiPathways,,EGF/EGFR signaling pathway,0.0349,PRKCD|JUN,29626,29721|29733,0.0051,,WP437,0.16037252,0
57,2,GO Biological Process,,Positive regulation of cell-matrix adhesion,0.0356,GSK3B|SMAD3,29626,29745|29715,6.70E-04,,GO:0001954,0.159423324,0
183,2,KEGG Pathways,,Viral carcinogenesis,0.0358,CDK2|JUN,29626,29727|29733,0.0064,,hsa05203,0.159155552,0
165,2,WikiPathways,,Chemokine signaling pathway,0.0359,GSK3B|PRKCD,29626,29745|29721,0.0052,,WP3929,0.159022226,0
72,2,Reactome Pathways,,Regulation of RUNX2 expression and activity,0.036,GSK3B|WWP1,29626,29745|29751,0.0011,,HSA-8939902,0.158889272,0
34,2,GO Molecular Function,,Disordered domain specific binding,0.0362,SMAD2|CTNNB1,29626,29730|29742,2.50E-04,,GO:0097718,0.158624466,0
2674,7,GO Biological Process,,Protein modification process,0.0363,RARA|SMAD2|CDK2|GSK3B|PRKCD|WWP1|CTNNB1,29626,29739|29730|29727|29745|29721|29751|29742,6.90E-04,,GO:0036211,0.158492612,0
654,4,GO Biological Process,,Chordate embryonic development,0.0363,RARA|SMAD2|SMAD3|CTNNB1,29626,29739|29730|29715|29742,6.90E-04,,GO:0043009,0.158492612,0
186,2,KEGG Pathways,,Chemokine signaling pathway,0.0363,GSK3B|PRKCD,29626,29745|29721,0.0066,,hsa04062,0.158492612,0
658,4,GO Biological Process,,Regulation of cell activation,0.037,RARA|PRKCD|MYB|CTNNB1,29626,29739|29721|29748|29742,7.10E-04,,GO:0050865,0.157579677,0
60,2,GO Biological Process,,Positive regulation of epithelial cell differentiation,0.0387,CYP27B1|CTNNB1,29626,29718|29742,7.40E-04,,GO:0030858,0.155432545,0
668,4,GO Biological Process,,Regulation of MAPK cascade,0.0387,PRKCD|JUN|MYC|CTNNB1,29626,29721|29733|29736|29742,7.50E-04,,GO:0043408,0.155432545,0
60,2,GO Biological Process,,Cellular senescence,0.0387,CDK2|PRKCD,29626,29727|29721,7.40E-04,,GO:0090398,0.155432545,0
198,3,GO Molecular Function,,Phosphatase binding,0.039,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,2.80E-04,,GO:0019902,0.155063452,0
77,2,Reactome Pathways,,Nuclear events mediated by NFE2L2,0.0404,GSK3B|MYC,29626,29745|29736,0.0012,,HSA-9759194,0.153377733,0
33,2,TISSUES,,Mesoderm,0.0409,MYB|CTNNB1,29626,29748|29742,2.40E-04,,BTO:0000839,0.152789814,0
287,3,GO Biological Process,,Ossification,0.0414,CYP27B1|SMAD3|CTNNB1,29626,29718|29715|29742,8.10E-04,,GO:0001503,0.152209039,0
43,2,COMPARTMENTS,,Euchromatin,0.0429,JUN|CTNNB1,29626,29733|29742,3.90E-04,,GOCC:0000791,0.15050789,0
64,2,GO Biological Process,,Positive regulation of dephosphorylation,0.043,PRKCD|SMAD3,29626,29721|29715,8.40E-04,,GO:0035306,0.150396604,0
81,2,Reactome Pathways,,Senescence-Associated Secretory Phenotype (SASP),0.0439,CDK2|JUN,29626,29727|29733,0.0013,,HSA-2559582,0.149406523,0
65,2,GO Biological Process,,Glandular epithelial cell differentiation,0.044,RARA|CTNNB1,29626,29739|29742,8.70E-04,,GO:0002067,0.149297769,0
82,2,Reactome Pathways,,Cyclin E associated events during G1/S transition,0.0443,CDK2|MYC,29626,29727|29736,0.0014,,HSA-69202,0.148972985,0
66,2,GO Biological Process,,Energy reserve metabolic process,0.0451,GSK3B|MYC,29626,29745|29736,8.90E-04,,GO:0006112,0.148117531,0
84,2,Reactome Pathways,,Cyclin A:Cdk2-associated events at S phase entry,0.0451,CDK2|MYC,29626,29727|29736,0.0014,,HSA-69656,0.148117531,0
68,2,GO Biological Process,,Cellular response to retinoic acid,0.0473,RARA|GSK3B,29626,29739|29745,9.50E-04,,GO:0071300,0.145841042,0
712,4,GO Biological Process,,Regulation of cellular response to stress,0.0473,GSK3B|PRKCD|MYC|CTNNB1,29626,29745|29721|29736|29742,9.50E-04,,GO:0080135,0.145841042,0
44,2,TISSUES,,Kidney cell line,0.0474,CYP27B1|MYC,29626,29718|29736,4.10E-04,,BTO:0000067,0.145740098,0
224,3,TISSUES,,Fibroblast,0.0474,SMAD2|SMAD3|MYC,29626,29730|29715|29736,4.00E-04,,BTO:0000452,0.145740098,0
7004,11,TISSUES,,Gland,0.0474,CYP27B1|SMAD2|GSK3B|PRKCD|SMAD3|MYB|JUN|RXRB|WWP1|MYC|CTNNB1,29626,29718|29730|29745|29721|29715|29748|29733|29724|29751|29736|29742,4.10E-04,,BTO:0000522,0.145740098,0
568,4,TISSUES,,Adenocarcinoma cell,0.0474,SMAD2|RXRB|WWP1|CTNNB1,29626,29730|29724|29751|29742,4.10E-04,,BTO:0000604,0.145740098,0
69,2,GO Biological Process,,Negative regulation of wound healing,0.0483,PRKCD|SMAD3,29626,29721|29715,9.70E-04,,GO:0061045,0.144841064,0
88,2,Reactome Pathways,,MAPK6/MAPK4 signaling,0.0487,JUN|MYC,29626,29733|29736,0.0016,,HSA-5687128,0.144446858,0
70,2,GO Biological Process,,Mesoderm formation,0.0493,SMAD2|SMAD3,29626,29730|29715,0.001,,GO:0001707,0.143861578,0
17,2,DISEASES,,Colon cancer,0.0493,MYC|CTNNB1,29626,29736|29742,6.82E-05,,DOID:219,0.143861578,0
17,2,DISEASES,,Hepatocellular carcinoma,0.0493,MYC|CTNNB1,29626,29736|29742,6.82E-05,,DOID:684,0.143861578,0
1901,7,Monarch Phenotype,,Abnormal oral cavity morphology,0.0497,CYP27B1|RARA|SMAD2|PRKCD|SMAD3|MYC|CTNNB1,29626,29718|29739|29730|29721|29715|29736|29742,7.98E-05,,HP:0000163,0.143475336,0
350,4,Monarch Phenotype,,Dyspnea,0.0497,RARA|SMAD2|SMAD3|CTNNB1,29626,29739|29730|29715|29742,6.43E-05,,HP:0002094,0.143475336,0
24,2,Monarch Phenotype,,Subarachnoid hemorrhage,0.0497,SMAD2|SMAD3,29626,29730|29715,1.30E-04,,HP:0002138,0.143475336,0
130,3,Monarch Phenotype,,Intracranial hemorrhage,0.0497,SMAD2|SMAD3|CTNNB1,29626,29730|29715|29742,8.17E-05,,HP:0002170,0.143475336,0
145,3,Monarch Phenotype,,Abnormal venous morphology,0.0497,PRKCD|SMAD3|CTNNB1,29626,29721|29715|29742,1.10E-04,,HP:0002624,0.143475336,0
147,3,Monarch Phenotype,,Abnormal lymph node morphology,0.0497,RARA|PRKCD|MYC,29626,29739|29721|29736,1.20E-04,,HP:0002733,0.143475336,0
22,2,Monarch Phenotype,,Ascending aortic dissection,0.0497,SMAD2|SMAD3,29626,29730|29715,1.10E-04,,HP:0004933,0.143475336,0
16,2,Monarch Phenotype,,Descending thoracic aorta aneurysm,0.0497,SMAD2|SMAD3,29626,29730|29715,6.11E-05,,HP:0004959,0.143475336,0
17,2,Monarch Phenotype,,Abdominal aortic aneurysm,0.0497,SMAD2|SMAD3,29626,29730|29715,6.82E-05,,HP:0005112,0.143475336,0
821,5,Monarch Phenotype,,Generalized abnormality of skin,0.0497,RARA|SMAD2|PRKCD|SMAD3|CTNNB1,29626,29739|29730|29721|29715|29742,1.20E-04,,HP:0011354,0.143475336,0
17,2,Monarch Phenotype,,Carotid artery dilatation,0.0497,SMAD2|SMAD3,29626,29730|29715,6.82E-05,,HP:0012163,0.143475336,0
18,2,Monarch Phenotype,,Descending aortic dissection,0.0497,SMAD2|SMAD3,29626,29730|29715,7.58E-05,,HP:0012499,0.143475336,0
17,2,Monarch Phenotype,,Paroxysmal dyspnea,0.0497,SMAD2|SMAD3,29626,29730|29715,6.82E-05,,HP:0012763,0.143475336,0
19,2,Monarch Phenotype,,Bone marrow hypercellularity,0.0497,RARA|PRKCD,29626,29739|29721,8.37E-05,,HP:0031020,0.143475336,0
22,2,Monarch Phenotype,,Abnormal ascending aorta morphology,0.0497,SMAD2|SMAD3,29626,29730|29715,1.10E-04,,HP:0031784,0.143475336,0
20,2,Monarch Phenotype,,Dural ectasia,0.0497,SMAD2|SMAD3,29626,29730|29715,9.21E-05,,HP:0100775,0.143475336,0
16,2,Monarch Phenotype,,Mucoid extracellular matrix accumulation,0.0497,SMAD2|SMAD3,29626,29730|29715,6.11E-05,,HP:0200146,0.143475336,0
